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Background: Bacterial infections remain one of the top causes of death worldwide despite 
the continuous development of conventional methods to eradicate this challenge. 
Mycobacterium tuberculosis (M.tb), a causative agent of tuberculosis (TB), is amongst the 
leading causes of mycobacterial mortality worldwide. Given the constant increase in TB 
incidence rates, there is a great need for better diagnostic and treatment methods for M.tb. 
Several studies have proposed the possible therapeutic role of vitamin D in antimycobacterial 
immunity. Vitamin D has been shown to boost the immune system against several ailments 
including TB, however, the exact mechanism through which vitamin D functions in 
antimycobacterial immunity remains elusive. In addition, the current conventional methods 
used to study the metabolism of vitamin D in the presence of mycobacteria are limited in 
terms of efficiency. As such, applying metabolomics to elucidate bacterial activity and vitamin 
D supplementation effects, at cellular level, could provide insight into the metabolic 
reprogramming associated with vitamin D during mycobacterial infection. Metabolomics is a 
multidisciplinary ‘omics’ science that deals with the identification and quantification of the 
metabolic changes in a biological system under specific conditions. This ‘omics’ field has 
shown promise in its ability to distinguish TB infected serum/plasma from uninfected 
serum/plasma. Metabolomics has been used to identify metabolic changes induced by M.tb 
infection; however, the metabolic reconfigurations induced by vitamin D in M.tb infection still 
need to be explored. Thus, the aim of this study was to evaluate the metabolic effects of 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), an active form of vitamin D, on the metabolome of U937 
macrophages stimulated with Pam3CSK4 (a mycobacterial model). Methods: Cultured U937 
monocytic cells were differentiated into macrophages using phorbol myristate acetate (PMA). 
Differentiation was confirmed by evaluating morphological changes of the cells and through 
flow cytometry evaluation of differentiation surface marker CD14. Following this, the cells 
were treated with Pam3CSK4 to stimulate bacterial infection and immunomodulatory effects 
towards bacterial lipoproteins. Furthermore, the cells were supplemented with vitamin D 
(1,25(OH)2D3). An untargeted NMR and GC-MS-based metabolomic approach where then 
conducted to characterise differential metabolic profiles of Pam3CSK4 stimulated cells, 
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1,25(OH)2D3 supplemented cells, a combination of Pam3CSK4 and 1,25(OH)2D3 
supplementation as well as the untreated cells. Results: Chemometric modelling and 
statistical analyses revealed a clear distinction between the metabolic profiles of Pam3CSK4 
stimulated cells, 1.25(OH)2D3 supplemented cells and cells supplemented with a combination 
of Pam3CSK4/1.25(OH)2D3 as compared to the control cells (untreated). Significant differences 
(p<0.05) were identified in 23 metabolites. These changes were detected in spectral regions 
related to methionine, galactose, myoinositol, threonine, glycine, beta-glucose, o-
phosphocholine, valine, lactate, mannose, taurine, adenosine monophosphate, ornithine, 
glycerol, succinate, tyrosine, phenylalanine, glutamate, leucine, pyroglutamate, glutathione, 
beta-alanine and glutamine. Alterations in these metabolites have been linked to changes in 
bioenergy production (up-regulation of glycolysis – the Warburg effect), regulation of redox 
reaction, inflammation and protein synthesis. Likewise, the metabolic profile of Pam3CSK4 
stimulated cells compared to Pam3CSK4/1.25(OH)2D3, showed significant differences in 
spectral regions of the aforementioned metabolites. These differences suggest that 
1.25(OH)2D3 induces metabolic reprogramming in Pam3CSK4 stimulated cells, by boasting 
macrophage immune response against mycobacteria. Conclusion: NMR- and GC-MS-based 
metabolomics successfully detected and identified metabolites discriminating a TLR2/1 
stimulated response (Pam3CSK4 and 1.25(OH)2D3 treatment). In addition, this multi-platform 
metabolite profiling allowed the characterisation of the metabolic alterations induced by 
Pam3CSK4 stimulation, 1.25(OH)2D3 supplementation and a combination of 
Pam3CSK4/1.25(OH)2D3. Results obtained show that 1.25(OH)2D3 promotes the elimination of 
bacterial infection by the macrophage and is therefore beneficial in the immune response 
against mycobacterial infection. Perspective studies will include quantitative analysis of 
metabolites implicated and the use of additional analytical techniques such as liquid 
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Tuberculosis (TB), a contagious disease that is airborne and caused by Mycobacterium 
tuberculosis (M.tb), remains a major threat worldwide as it is an ancient disease that has 
caused millions of deaths (Soto-Ramirez et al., 2016; Zumla et al., 2013). According to the 
World Health Organisation (WHO), at least 10 million people, globally, are diagnosed with TB 
each year. TB is also a poverty-related disease with 95% incidence rates reported in 
developing countries (Barter et al., 2012; Okhovat-Isfahani et al., 2019). Africa alone accounts 
for 24% of all TB cases, which makes it the second-highest after South-East Asia (44%) (WHO, 
2019). Given the constant increase in TB incidence rates, there remains a great need for better 
diagnostic methods and treatments for TB. The diagnosis and treatment of TB are currently 
very challenging for two key reasons. Firstly, resistance in M.tb is a common occurrence; for 
instance, in 2018 it was estimated that there were already over half a million new multidrug-
resistant  cases (WHO, 2019). Secondly, co-infection with Human Immunodeficiency Virus 
(HIV) is also very common and poses a greater challenge in diagnosis and treatment 
interventions. In South Africa, more than 60% of individuals infected with TB also test HIV 
positive, thus making South Africa the epicentre of HIV/TB co-infection (WHO, 2018).  
In the pre-antibiotics era, natural remedies such as the use of cod liver oil and sunlight 
exposure were used as a form of TB therapeutics. Most recently, several studies have 
suggested the possible therapeutic role of Vitamin D in antimycobacterial immunity (Dini and 
Bianchi, 2012; Salahuddin et al., 2013). Vitamin D has been shown to boost the immune 
system against several ailments including TB (Marques et al., 2010; Thacher and Clarcke 
2011). When supplemented with vitamin D, TB patients show an accelerated clinical recovery 
rate (Salahuddin et al., 2013). Furthermore, vitamin D supplementation decreases the 
activation and the progression of latent TB (LTB) to active TB (Arnedo-Pena et al., 2015). The 
exact mechanisms through which vitamin D functions in antimycobacterial immunity, 
however, remains elusive. Additionally, there is limited knowledge of the metabolic effect of 
vitamin D during mycobacterial infection. For this reason, the role of vitamin D during 
mycobacterial infection needs to be explored so as to understand how vitamin D affects the 
metabolic pathways involved in mycobacterial infection. 
The emerging latest cardinal omics approach, metabolomics, has provided new possibilities 
of understanding the metabolic reprogramming of a biological system associated with a 
stimulus. Recently, high throughput and high sensitivity techniques such as nuclear magnetic 
resonance (NMR) spectroscopy, mass spectrometry (MS)-based platforms (such as gas 
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chromatography-–mass spectrometry spectrometry, GC-MS), infrared spectroscopy and 
Raman spectroscopy have found use in metabolomics. Nicholson et al. (1999) defined 
metabolomics as a multidisciplinary ‘omics’ science that evaluates the metabolic changes of 
a biological system by identifying and quantifying the small molecular weight molecules 
(metabolites), components of metabolism, under specific conditions. Metabolomics has been 
successfully used to determine the efficacy of pharmaceutical drugs, assessment of drug 
toxicity, identification of disease biomarkers, enzyme discovery, determining the quality and 
safety of food, and exploration of metabolic networks in systems biology (Clayton et al., 2006; 
Gomez-Casati et al., 2013; Liu et al., 2018). Available metabolomics software and databases 
allow for the identification of the metabolic pathways associated with the altered metabolites 
under specific conditions. Ultimately, metabolomics can identify metabolites associated with 
a perturbation, therefore, providing reliable biomarkers for a disease. Hence, metabolomics 
is used in diagnostic test development (German et al., 2005).   
Metabolomics investigations of TB infected biofluids have been extensively performed (as 
reviewed by Mirsaeidi et al., 2015). Using 1H NMR, Vrieling et al. (2018) and Zhou et al. (2013) 
identified plasma-based and serum biomarkers in TB patients. Furthermore, Dang et al. (2013) 
used GC-MS to identify M.tb infection biomarkers in culture, serum and urine. In other 
studies, Du Preez and Loots (2013) and Loots (2014) used two-dimensional gas 
chromatography coupled with time-of-flight mass spectrometry (GCxGC–TOFMS) to detect 
M.tb associated metabolites in sputum and mycobacterial cultures, respectively. Currently, 
no study has investigated the metabolic effect of vitamin D supplementation in TB infected 
cells using a metabolomics approach. As such, the main aim of this study was to make use of 
an NMR and GC-MS-based metabolomics approach to measure the metabolic reprogramming 
induced by vitamin D supplementation, in the presence of mycobacterial elicitor to mimic 
infection, in macrophages. This is aimed at identifying metabolites markers associated with 
mycobacterial infected cells in response to vitamin D in order to identify the specific metabolic 
pathways targeted by vitamin D. Taken together, this information can be used to determine 
the effectiveness of vitamin D in the immune response against mycobacterial infection. 
In the present study, tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)4 (Pam3CSK4), a synthetic 
mycobacterium that elicits toll-like receptor (TLR) 2/1, was used to stimulate U937 
macrophages in vitro. The stimulated macrophages were supplemented with 1,25-
dihydroxycholecalciferol (1,25(OH)2D3), an active form of vitamin D to evaluate its metabolic 
effect using NMR and GC-MS–based metabolomics.  
The following chapter (Chapter 2) gives a detailed review of topics related to this study. This 
is followed by the hypothesis, aim, objectives, and study workflow. The succeeding chapter 
(Chapter 3) gives detailed materials and methods used to achieve the aim of the study. 
Chapter 4 provides the generated results. The detailed discussion of each set of results is 
given in Chapter 5. The overall conclusion and future perspective are given in Chapter 6. 
Chapter 7 provides the comprehensive list of references used in this study, followed by the 
3 
 
appendix. The appendix at the end of the dissertation consists of all additional and 
































Bacterial infections are among the top causes of disease-related deaths worldwide (Raoult et 
al., 2019) with mycobacteria being the main contributor. Mycobacterium is a member of the 
genus actinobacteria with several species classified into tuberculous or nontuberculous 
mycobacteria (NTM). Whilst tuberculous bacteria are disease-causing (e.g. TB), NTM are less 
pathogenic in humans. The latter mainly cause opportunistic infections in 
immunocompromised individuals (Tortoli, 2009). Mycobacterium of TB in humans. TB is the 
leading cause of infectious disease-related deaths worldwide. Moreover, one-third of the 
world’s population is latently infected with M.tb. (Osman et al., 2017; Soto-Ramirez et al., 
2017; Zumla et al., 2013). Thus, TB remains a worldwide threat. The prevalence of M.tb 
infection is also accelerated by the development of new strains of M.tb, some of which are 
resistant to the available anti-TB drugs (Chandra et al., 2016). Hence, there is a great need for 
a better understanding of the biochemistry, metabolism, and pathogenesis of mycobacteria 
as this is crucial for controlling mycobacterial infections. Therefore, timely, accurate and easy-
to-use detection methods for mycobacteria are required (Palomino, 2005). In an attempt to 
study exposure to M.tb, in vitro models for immune cell stimulation have been developed. 
Tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)4, commonly known as Pam3CSK4, is an M.tb lipoprotein 
mimic used to stimulate immune cells in in vitro models (Akira et al., 2006).  
2.2. Pam3CSK4 
Pam3CSK4 is a synthetic molecule that mimics bacterial triacylated lipoprotein of a wide range 
of bacteria (Figure 2.1), including M.tb, Neisseria meningitidis, Trypanosoma cruzi and 
zymosan of yeast cell wall (Nyirenda et al., 2013). Pam3CSK4 stimulates immunomodulatory 
effects similar to those observed against lipoproteins from these bacteria (Akira et al., 2006; 
Aliprantis et al., 1999). Pam3CSK4 consists of carboxy terminal amino acids and N-acyl-S-
diacylglyceryl cysteine and can therefore mimic the acylated amino terminus of bacterial 
lipopeptides. As such, Pam3CSK4 has captured the interest of many researchers working on in 
vitro based bacterial research, particularly those concerned with the study of Toll-like 
receptors (TLRs), especially TLR 2 and 1 (Du et al., 2011; Zhang et al., 2016; Zhu et al., 2018; 
Zom et al., 2018). Both Pam3CSK4 and bacterial triacylated lipoprotein stimulate the 




Figure 2.1: Structural representation of a bacterial triacylated lipoprotein (A) and Pam3CSK4 (B). Both 
have three lipid chains with one lipid chain attached to the N-terminal of cysteine. Both molecules 
induce an immunomodulatory effect through the acylated N-terminal cysteine. Adapted from 
Schromm, 2007; Wiktor et al., 2017. 
 
Pam3CSK4 is recognised by the Toll-like receptor 2/1 (TLR 2/1) protein, a membrane-bound 
dimer TLR receptor on the cell surface. TLRs form a major part of the innate immune response 
as they recognise pathogens and transduce a signal to activate downstream pathways that 
initiate the mechanisms responsible for the elimination of the pathogen. The downstream 
pathways stimulated by the activation of TLR2/1 by Pam3CSK4 are summarised in Figure 2.2.  
 
 
Figure 2.2: Pam3CSK4-induced stimulation of heterodimer TLR 2/1.TLR2/1 activation by Pam3CSK4 is 
associated with elevated expression of NF-kB, which stimulates the production and release of 
cytokines such as TNF-α, IL-6 and IL-12. TLR2/1 activation is also associated with the activation 
(opening) of α1β1 integrin receptor to initiate the endocytosis of the Pam3CSK4-TLR 2/1 complex. The 
resulting endolysosome further secretes type 1 interferon and IL-6 to signal neighbouring cells about 
the infection.  Abbreviations: α1β1: alpha-1 beta-1 integrin; TLR2/1: Toll-like receptor 2/1; Pam3CSK4: 
Tripalmitoyl-S-glyceryl-L-Cys-Ser-(Lys)4; NF-kB: Nuclear Factor kappa beta; TNF-α: Tumour necrosis 
factor- alpha; IL-6: Interleukin 6; IL-12: Interleukin 6. Adapted from Marre et al., 2010. 
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The focus of this study was on M.tb and as such, Pam3CSK4 was used to mimic for 
mycobacteria. Pam3CSK4 can provide a good starting point for understanding common, 
underlying mechanisms of M.tb pathogenesis. In addition, Pam3CSK4 provides a good tool to 
study mechanisms associated with TLR2 activation, the main TLR that initiates host immune 
response towards M.tb infection (Xue et al., 2008). Pam3CSK4 may thus shed light on the 
disease mechanisms associated with M.tb. Both M.tb infection and Pam3CSK4 share common 
biological effects such as the secretion of pro-inflammatory cytokines including IL-1, IL-6, IL-
23 and TNF-α. The production of reactive oxygen species (ROS) is also observed in both cases 
(Bardoel et al., 2014; Yang et al., 2012). 
 
2.3. Vitamin D 
Prior to the antibiotic era, vitamin D was used to boost the immune system against several 
diseases including infectious diseases, inflammatory diseases, hypertension, diabetes mellitus 
and auto-immune diseases (Marques et al., 2010; Thacher and Clarcke, 2011). Vitamin D 
deficiency has been associated with immune response disorders. Interestingly, vitamin D was 
used for TB treatment (Wejse et al., 2009; Wu et al., 2018). Findings have shown that 
individuals with TB have less vitamin D than healthy individuals (Gao et al., 2014). When 
supplemented with vitamin D, TB patients show ease in the disease symptoms. Furthermore, 
vitamin D supplementation decreases the activation and the progression of latent TB (LTB) to 
active TB (Arnedo-Pena et al., 2015). In their study, Talat et al. (2010) reported that individuals 
with vitamin D deficiency are five times more likely to develop active TB compared to those 
with sufficient vitamin D. People of African descent are commonly known to have low vitamin 
D levels and are more likely to get TB than individuals from European descent (Green et al., 
2015). Accordingly, TB is more common in African countries (Barter et al., 2012).  
 
2.3.1. Vitamin D and its metabolism 
Vitamin D is an essential steroid hormone acquired from vitamin D rich nutritional sources, 
vitamin D supplements and through ultraviolet B (UVB) radiation-dependent synthesis (Prietl 
et al., 2013).  Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) are two well-known 
forms of the hormone vitamin D. Whilst vitamin D2 originates from ergosterol UV radiation in 
fungi and some plants, vitamin D3 originates from the UV radiation of 7-dehydrocholesterol 
to form previtamin D3 in animals’ skin (Tripkovic et al., 2012). Humans self-synthesize 
cholecalciferol and acquire ergocalciferol from vitamin D supplements and dietary sources 
such as fish, eggs and cheese (Kulie et al., 2009). 1,25(OH)2D3 is an active form of vitamin D 
with various biological effects. The classical biological functions of this hormone include the 
regulation of minerals such as calcium and phosphate homeostasis to promote bone health 
(Prietl et al., 2013). 1,25(OH)2D3 further promotes the proliferation and differentiation of cells 
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such as osteoclast, endothelial cells, lymphocytes and keratinocytes (Khammissa et al., 2018). 
1,25(OH)2D3 has been shown to also regulate the innate and adaptive immune response 
(Chun et al., 2014). 
UVB radiation-dependent synthesis of vitamin D involves the photolytic conversion of 7-
dehydrocholesterol—a precursor of vitamin D—to pre-vitamin D3 in the lower epidermis of 
the skin. Pre-vitamin D3 is then converted to vitamin D3 (cholecalciferol), similar to that 
obtained in dietary sources and supplements. Vitamin D3 binds to vitamin D binding protein 
(DBP), which transports vitamin D3 to the liver to be enzymatically converted to 25-
hydroxyvitamin D (25(OH)D), the main circulating inactive form of vitamin D through 
hydroxylation by 25-hydroxylase. 25(OH)D has the longest half-life and hence it is used to 
determine vitamin D status (Zhang and Naughton, 2010). 25(OH)D circulates to the kidneys 
or any tissue that express 1α-hydroxylase (CYP27B1) such as the cerebellum, osteoblasts, 
pancreatic islets, placenta, monocytes, macrophages and dendritic cells (Hewison, 2012; 
Owens et al., 2018;), where it is hydroxylated to the circulating active metabolites of vitamin 
D. Although the conversion of 25(OH)D to 1,25(OH)2D3 can also occur under normal, healthy 
conditions, monocytes and macrophages, among other immune cells produce high levels of 
1,25(OH)2D3 through CYP27B1 following the activation of these cells by the pathogen. 
Pathogen-dependent activation of immune cells is associated with an increased expression of 
vitamin D receptor (VDR) and 1α-hydroxylase, CYP27B1 (Figure 2.3). In addition to 
1,25(OH)2D3 production in the kidney, enzyme 24-hydroxylase (CYP24A1) hydroxylates C-24 
of 25(OH)D3 to yield 24,25(OH)2D3, a less active vitamin D hormone as compared to 










Figure 2.3: Vitamin D-mediated innate immune response following activation of TLR2/1 by a 
bacterial pathogen. The activation of TLR2/1 is linked with the conversion of 25D to 1,25D by enzyme 
CYP27B1. Subsequently, VDR binds 1,25D and stimulates the expression of CAMP and DEFB4. Bacterial 
killing is also achieved through autophagy and formation of autophagosomes. The suppression of 
HAMP regulates ferroportin, which promotes the extracellular transportation of Fe to facilitate 
bacterial elimination. IL-1R is stimulated to bind IL-1, which promotes the synthesis of NF-ĸB. Together 
with MDP binding to NOD2, NF-ĸB provides an additional response to facilitate the interaction of VDR 
with 1,25D, therefore facilitating the bacterial elimination. Abbreviations: 1,25D: 1,25-dihydroxy 
vitamin D; 25D: 25-hydroxyvitamin D; CAMP: Cathelicidin antimicrobial peptide; CYP27B1: 1α-
hydroxylase; DEFB4: β-defensin 4; Fe: Iron; HAMP: Hepcidin antimicrobial peptide; IL-1: interleukin 1; 
IL-1R: Interleukin 1 receptor; MDP: muramyl dipeptide; NF-ĸB: Necrosis factor-kappa beta; NOD2: 
Nuclear-binding oligomerization domain-containing protein 2; TLR2/1: Toll-like receptor 2/1; VDR: 
Vitamin D receptor.  Adapted from Chun et al., 2014. 
 
2.3.2. Regulation of vitamin D metabolism 
The regulation of vitamin D metabolism is achieved through the regulation of enzymes 
CYP27B1 in the kidney and 25-hydroxylase in the liver. 1α-Hydroxylase is more tightly 
regulated as compared to 25-hydroxylase since it controls 1,25(OH)2D3 synthesis (Kochupillai, 
2008). At low concentrations of 1,25(OH)2D3, parathyroid hormone induces 1α-hydroxylase to 
favour 1,25(OH)2D3 synthesis (Christakos, 2017). The increase in the levels of 1,25(OH)2D3 
eventually results in a feedback mechanism that triggers an increase in the level of bone 
fibroblast growth factor 23 (FGF23). FGF23 is a phosphaturic hormone produced by 
osteocytes and osteoblasts. This hormone inhibits 1α-hydroxylase expression to decrease 
1,25(OH)2D3 synthesis (Khammissa et al., 2018). Simultaneously, increasing levels of FGF23 
induces the expression of 24-hydroxylase, an enzyme that catalyses the conversion of 
25(OH)D3 to a less active vitamin D metabolite, 24,25(OH)2D3 in the kidneys (Perwad and 
Portale, 2011).   
9 
 
2.3.3. Role of 1,25(OH)2D3 in innate immunity 
TLR2/1-pathogen interaction activates an innate immune defence mechanism strengthened 
by 1,25(OH)2D3. This form of immunity comprises chemotactic and phagocytic processes of 
monocytes and macrophages (Purnamasari et al., 2014). The activation of vitamin D-–
mediated innate immunity depends on the recognition of pathogen-–associated molecular 
patterns (PAMPs) by pattern-recognition receptors (PRRs) such as TLR2/1. Upon pathogen 
perception by TLR2/1, liganded VDR binds the retinoid X receptor (RXR) to form a heterodimer 
that binds a specific gene sequence called a vitamin D response element (VDRE). Liganded 
VDR–RXR heterodimer is responsible for the activation of hundreds of target genes or 
repression by recruiting coactivators or coreceptors, respectively, to a particular target gene 
(Christakos et al., 2016; Rosen et al., 2012). These mechanisms result in the expression or 
suppression of target genes with biological effects that will favour the elimination of the 
pathogen. β-Defensin 4 (DEFB4) and cathelicidin antimicrobial peptide (CAMP) are well 
known genes that encode antibacterial proteins β-defensin 2 and cathelicidin antimicrobial 
peptide, respectively. Collectively, these antibacterial proteins facilitate the elimination of the 
bacterial pathogen, Figure 2.3 (Baeke et al., 2010; Liu et al., 2006). 
In addition to the elimination of the bacteria by antibacterial proteins, autophagy and 
formation of autophagosomes following the activation of TLR2/1 also play a major role in 
pathogen elimination. Furthermore, accessory immune response mechanisms (shown in 
green in Figure 2.3) are also activated in response to increasing 1,25(OH)2D3. For instance, the 
expression of interleukin–1 receptor (IL-1R) and muramyl dipeptide is induced following the 
activation of TLR2/1 and production of 1,25(OH)2D3. IL-1R facilitates the binding and the entry 
of cytokine IL-1, which in turn, induces the expression of Necrosis factor-kappa beta (NF-ĸB) 
to facilitate pathogen elimination. In addition to these direct mechanisms of bacterial 
elimination, hepcidin antimicrobial peptide (HAMP) indirectly kills the pathogen by 
decreasing intracellular iron (Fe), which is needed to maintain bacterial growth and survival. 
HAMP primarily regulates ferroportin, the iron exporter located on the cell membrane (Ganz, 
2011).  
 
2.3.4. Role of 1,25(OH)2D3 in adaptive immunity 
The adaptive immune response also plays a crucial role as a second defence mechanism 
against pathogenic infection. The major key players in adaptive immunity include dendritic 
cells (CDs), B -cells and T -cells, including effector T -cells and regulatory T -cells due to their 
ability to express VDR in response to antigenic activation. 1,25(OH)2D3 has different biological 
effects in adaptive immunity in vitro and in vivo (Hewison, 2012). Briefly, dendritic cells—also 
known as antigen-presenting cells (APCs)—are the first immune cells of the adaptive immune 
response triggered by 1,25(OH)2D3 signalling. DCs capture the antigen for processing and 
presentation to the T cells (Purnamasari et al., 2014). It was first thought that 1,25(OH)2D3 
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suppresses T cell proliferation; however, subsequent studies revealed that the effects of 1,25 
(OH)2D3 are dependent on the phenotype of the T cell. Thus, high levels of 1,25(OH)2D3 are 
associated with down-regulation of T helper cell 1 (Th1) and T helper cell 17 (Th17), causing 
inhibition of proinflammatory cytokines associated with these T helper cells such as 
interferon- gamma (IFN-γ), IL-2, IL-17 and IL-21. On the other hand, T helper cell 2 (Th2) and 
Treg are up-regulated, resulting in an increase in IL-4 and IL-10 (Hewison, 2012). The biological 
significance of switching from Th1 to Th2 phenotype is to limit the tissue damage resulting 
from excessive Th1. Th17, on the other hand, has been linked not only with promoting 
immune response but also with promoting inflammatory tissue damage, hence it is down-
regulated by 1,25(OH)2D3 (Korn et al., 2007).  
Activated T cells indirectly stimulate B cell activation through mechanisms including the 
suppression of immunoglobulin (Ig) secretion, inhibition of proliferation and differentiation 
of plasma cells as well as the stimulation of B cell apoptosis (Purnamasari et al., 2014). B cells 
use autocrine mechanisms to produce their own 1,25(OH)2D3 that regulates immunity. In 
addition, B cells stimulate increased expression of IL-10, a cytokine that inhibits the 
presentation of the antigen by DCs and macrophages as well as the inhibition of T cell 
activation (Heine et al., 2008). The biological significance of 1,25(OH)2D3 mediated adaptive 
immune response is to balance the activity of the immune response, therefore preventing the 
tissue damage resulting from excessive cytokines and anti-microbial proteins (Handono et al., 
2012). 
 
2.3.5. Vitamin D status and deficiency: why it happens, prevalence and consequences 
 
Vitamin D deficiency is one of the major health problems worldwide across all age groups 
(Regmi et al., 2017). Vitamin D status is determined using 25(OH)Dlevels since it is the main 
circulating form of vitamin D and has a long half-life during circulation (Zhang and Naughton, 
2010). The concentration of 25(OH)D used to determine whether this hormone is deficient or 
not remains unclear. The United States Institute of Medicine, however, defined a 
concentration of <30 nmol/L 25(OH)D as deficient, 30–49 nmol/L as insufficient and 50–125 
nmol/L as sufficient (Looker et al., 2011). Vitamin D deficiency occurs when the serum level 
of vitamin D is extremely low which could be alluded to inadequate dietary uptake or reduced 
vitamin D synthesis, most probably from decreased sunlight exposure (Nighat et al., 2010). 
Additionally, obesity, age, race, dark skin pigmentation, season, latitude and the use of 
sunscreen also contribute towards vitamin D deficiency (Souberbielle, 2016; Zhang and 
Naughton, 2010). This health problem is also associated with an increased risk of neoplastic, 
immune and metabolic disorders (Holick, 2007). In children, vitamin D deficiency is associated 
with rickets whereas in adults it is associated with osteomalacia, multiple sclerosis, 
cardiovascular diseases and chronic diseases (Cantorna et al., 2004; Holick, 2007; Wu et al., 
2007). Moreover, individuals with vitamin D deficiency are more susceptible to infectious 
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diseases as opposed to healthy individuals (Garg et al., 2016). The levels of serum vitamin D 
can be improved by the intake of vitamin D dietary products and vitamin D supplements 
(Kennel et al., 2010). Although vitamin D supplementation has been shown to decrease the 
activation and the progression of latent TB (LTB) to active TB, the molecular mechanism of 
vitamin D in the presence of mycobacteria remains elusive. As such, the aim of this study was 
to make use of metabolomics in order to explore the role of vitamin D in immune response 
to TLR2/1 elicitation by a mycobacterial elicitor. 
 
2.4. Metabolomics 
2.4.1. The origin of metabolomics 
The use of metabolic profiling dates back as early as the 1950s (Williams, 1956) where it was 
used to understand complex biological systems before the term metabolome was even 
introduced to literature in September 1998 (Oliver et al., 1998). Subsequently, the term 
metabolomics and its equivalent term metabonomics were formulated at the end of the 
1990s (Oliver et al., 1998; Nicholson et al., 1999). The two terminologies, metabolomics and 
metabonomics, are often used interchangeably in the literature. The current study, however, 
uses the term metabolomics, as it describes a comprehensive analysis of as many metabolites 
as possible in a biological system (Clish, 2015). Metabolomics can thus be described as the 
detection and quantitative measurements of the metabolites in a biological system under 
specific conditions or perturbation. On the other hand, metabonomics is defined as the 
quantitative measurement of the metabolic changes of a living system in response to genetic 
modification or any pathophysiological stimulus (Nicholson et al., 1999). Thus, metabonomics 
emphasizes on the characterisation of the differences in metabolites due to genetic 
modification, disease, environmental stress or any other stimulus that perturbs the 
metabolism of the given organism (Ramsden, 2009).  
Metabolites are low molecular-mass compounds (<1.5 kDa) involved in metabolic processes 
of an organism and they are the endmost products of gene expression. The total number of 
metabolites of an organism—the metabolome—comprise amino acids, esters, lipids, steroids, 
carbohydrates, organic acids, oligopeptides, bile acids, nucleosides and nucleotides (Clarke 
and Haselden, 2008; Mirsaeidi et al., 2015). These are small molecules that are biologically 
essential for energy production and storage, signal transduction and apoptosis among other 
biological roles (Johnson et al., 2016). Despite being the youngest omics in the omics cascade, 
the use of metabolomics has grown quite rapidly over the past years, particularly in the 
medical field and in basic research. This is due to its promising ability in providing early clinical 
diagnostics, drug refinement, and personalised medicine (Riekeberg and Powers, 2017). The 
planning of a metabolomics experiment is determined by the aim of a study, however, a 




Figure 2.4: A typical metabolomics workflow. The diagram illustrates the common steps followed in 
a metabolomics experiment. It also highlights techniques used at different stages of metabolomics 
depending on the type of sample specimen being analysed and the aim(s) of the experiment. 
Abbreviations: ANOVA: Analysis of variance; CE: Capillary electrophoresis; FT-IR: Fourier-transform 
infrared; GC: Gas chromatography; HMDB: Human Metabolome Database; KEGG: Kyoto Encyclopedia 
of Genes and Genomes; LC: Liquid chromatography; MS: Mass spectrometry; NMR: Nuclear magnetic 
resonance; OPLS-DA: Orthogonal projections to latent structures–discriminant analysis; PCA: Principal 
component analysis. 
 
2.4.2. Metabolomics approaches 
Metabolomics studies take one of two approaches, namely the targeted or untargeted 
approach. The untargeted approach is a starting point for any metabolomics study as it 
focuses on the global profiling of as many metabolites as possible in a given biological system. 
More than one analytical platform is normally used in the untargeted approach to profile as 
many metabolites as possible. A new hypothesis is usually derived from the initial findings of 
the untargeted approach. In contrast, a targeted approach is a hypothesis-driven approach 
that focuses on profiling a group of predefined metabolites, usually with similar biological 
properties. It is therefore common in this approach that the physio-chemical properties and 
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structures of the metabolites of interest are known beforehand (Schrimpe-Rutledge et al., 
2016; Tzoulaki et al., 2014). The benefits of using a targeted over an untargeted approach 
include high sensitivity and increased maximum analytical throughput. Untargeted 
metabolomics is, however, more comprehensive and unbiased. The largest number of 
metabolites are therefore detected using the latter approach. Untargeted metabolomics is 
widely used for the discovery of novel metabolites and biomarkers. Despite these strengths, 
untargeted metabolomics remains less sensitive compared to the targeted approach 
(Kirkwood et al., 2013). Whilst the untargeted approach is crucial for metabolite discovery 
and relative quantification, the targeted approach is useful for validation and absolute 
quantification of the already known metabolites (Schrimpe-Rutledge et al., 2016).  
 
2.4.3. Why metabolomics over other omics technologies 
Metabolites are influenced by genetic and epigenetic processes, post-translational 
modifications, protein transport and signal transduction (Kell and Oliver, 2016; Likic et al., 
2010). Metabolomics can therefore provide comprehensive information from different 
molecular stages (Figure 2.5). Metabolomic analysis, in comparison to other omics, can also 
provide phenotypic information of an organism induced by various stimuli such as diseases 
and medication (Wishart et al., 2007). Understanding the changes in the metabolome 
resulting from a disease could play a crucial role in the development of better disease 
characterisation methods, diagnostics and treatment (Du Preez et al., 2019). Despite the 
change in the metabolome under various conditions, the basic chemical structure of a 
metabolite is similar throughout different species (Duft et al., 2017). As such, metabolites can 
provide more reliable and robust biomarkers for a perturbation (German et al., 2005). 
Another strength of metabolomics includes the ability to profile changes due to ‘silent 
mutation’ (Raamsdonk et al., 2001). Hence, metabolomics has the potential to provide useful 
disease biomarkers that give a better understanding of the underlying disease mechanisms. 
Biomarkers can be used to monitor disease at different stages such as early, latent or late 
stages (Atan et al., 2018; Du Preez et al., 2017). The advantages and disadvantages of the 






Figure 2.5: The omics cascade. The omics cascade showing the flow of molecular information from 
the genome, to epigenome, transcriptome, proteome and metabolome. Metabolomics is at the end 























Table 2.1: Comparison of main omics technologies, adapted from Diamandis et al., 2010; Draghici et al., 2006; Fliser et al., 2007; Jax et al., 2018; Johnson 
and Gonzalez, 2012; Kinoshita et al., 2006; Kuehnbaum and Britz-McKibbin, 2013; Kalantari et al., 2015; Lorincz, 2011; Mesri, 2014; Roberts and 
Middleton 2017; Serkova et al., 2011; Zhan, 2015; Zhao et al., 2014. 
Omics Description Strengths Weaknesses 
Genomics Concerned with the study 
of the whole genome. The 
complete set of all genes in 
an organism.  
• The available knowledge is substantial. 
• Genomics can be used to develop 
diagnostic, prognostic and treatment for 
patients. 
• Multiple genes can be identified 
simultaneously, allowing the detection of, 
e.g. altered gene(s) associated with a 
disease. 
• Unintended Identification of gene mutations not 
associated with the condition of interest may 
complicate result interpretation and lead to false 
conclusions. 
• Genes are sensitive to various stimuli such as 
disease and environmental factors. 
Epigenomics The study of the 
epigenome includes 
studies on DNA 
methylation, histone 
modification and RNA 
regulation. 
• Genetic information missed in gene 
expression profiles can be recovered in the 
epigenome. 
• Epigenetic profiles are highly stable. 
• Provides epigenetic biomarkers for 
diseases. 
• Diversity in epigenetic changes across tissue 
types. 
• Diagnosis of epigenetic changes may require 
several assays. 
• Susceptible to false discovery of new 
biomarkers. 
Transcriptomics The study of the 
transcriptome, the entire 
set of RNA molecules of an 
organism or a cell. 
• Gives a better understanding of gene 
expression and gives the possible 
functions, which would reflect the 
phenotype. 
• Many transcriptome studies use microarrays 
approach, which suffers from detecting very 
lowly expressed and novel transcripts 




Proteomics The study of proteins 
including their folding, 
localization, expression, 
function and interaction 
• Understanding of genomic information in 
terms of protein structures and functions. 
• The proteome is close to the biological 
function (phenotype). 
• Challenges in linking the proteome and the 
genome. 
• Lack of stability in the proteome during sample 
preparation may lead to false representation of 
the original proteome of an organism. 
Metabolomics The detection and 
quantitative 
measurements of the 
metabolites in a biological 
system under specific 
conditions or perturbation. 
• High throughput, sensitivity, and accuracy. 
• Qualitative and quantitative. 
• The ability to study a specific phenotype at 
a molecular level. 
• Metabolites correlate with the phenotype 
of an individual. 
• Availability of advanced analytical 
techniques. 
• Disease biomarker discovery. 
• Difficulties in metabolite identification and 
interpretation. 
• Many knowledge gaps in human metabolomics. 
• Data handling and processing can be 
challenging. 
• Metabolome can be altered by various genetic 
and environmental stimuli other than those of 
interest. 
• Variations between individuals in human 
metabolomics. 
• Metabolome complexity and variations. 
• Difficulties in translation of metabolites into 




2.4.4. Metabolomics analytical platforms 
The high reproducibility and high throughput provided by metabolomics are made possible 
by the availability of advanced sensitive and selective spectroscopy and spectrometry-based 
analytical techniques. These techniques make use of the emission, absorption or scattering 
of electromagnetic radiation by matter (atoms, molecules, ions or solids) for qualitative and 
quantitative analysis (Kalantri et al., 2010). Fourier transformation-infrared (FT-IR) 
spectroscopy, Raman spectroscopy, nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS) are the well-known metabolomics analytical techniques, however, 
NMR and MS are the most widely used techniques due to their high sensitivity and selectivity 
(Dunn and Ellis, 2005). Despite being the preferred techniques, NMR and MS also come with 
their own weaknesses (Table 2.2). Combining the two usually gives complementary 
information (Bingol and Brüschweiler, 2015). The choice of the analytical technique to use in 
a metabolomics experiment is influenced by the type of the biological system to be analysed 
as well as the aim of the experiment or question to be answered (Trygg et al., 2007). Despite 
the strength provided by each analytical platform, there is no single analytical platform that 
can detect the entire metabolome within a biological systemdue to the metabolite 
heterogeneity (Booth et al., 2013).  
 
Table 2.2: Comparisons of NMR and MS analytical platforms. Adapted from Carlos et al., 2011; Davis and 
Mauer, 2010; De Villiers and Loots, 2013; Faghihzadeh et al., 2016; Kalantri et al., 2010; Mogilevsky et al., 
2012. 




analysis of the 
magnetic 
properties of the 
atomic nuclei of 
a molecule under 
a magnetic field. 
• Non-destructive 
and therefore 
samples can be 
recovered. 
• Requires a minimal 
sample 
preparation. 
• Can simultaneously 
measure all kinds 
of metabolites. 
• Can be used for in 
vivo studies. 
• Less sensitive (as compared to mass 
spectroscopy). 
• Does not always accurately detect fats 
and lipids. 
• NMR spectra of biological samples are 
complex and hence large peaks may 










• High sensitivity and 
specificity. 
• Requires small 
sample size for 
analysis. 
• Qualitative and 
quantitative 
technique. 
• Extensive sample preparation is 
required. 
• Inability to measure many large 
biological molecules. 
• Destructive and hence samples cannot 
be recovered. 





• Can detect a wide 
dynamic range of 
metabolites. 
 
2.4.5. The basic principle of NMR spectroscopy 
Atomic nuclei of some atoms such as that of 1H, 13C and 31P consist of a spin, which is a 
property similar to atomic mass and charge (Demarest, 2015; Yabsley et al., 2012). The spin 
generates the magnetic field in the nucleus. This causes the random orientation of the spins, 
however when the atomic nuclei are subjected to the external magnetic field generated by 
the NMR spectrometer, two spin states are produced, one aligned with the external magnetic 
field and the other against the external magnetic field. The spin aligned with the external 
magnetic field is called the alpha (α) spin and has a lower energy state. The spin against the 
external magnetic, called the beta (β) spin, has a higher energy state (Antcliffe and Gordon, 
2016; Boyer, 2012; Zia et al., 2019). When the nuclei are subjected to the radiofrequency 
energy, α spin is excited to a higher energy state. The higher energy state is less stable and 
therefore the α spin will return to the lower energy state in a process known as relaxation. 
The α spin emits the absorbed radiofrequency energy as it returns to the lower energy state. 
The emitted radiofrequency energy is converted into a signal which is represented on the 
NMR spectrum (Figure 2.6). The horizontal x-axis of the NMR spectrum represents the 
resonant frequency as the chemical shift in parts per million (ppm). Nuclei of different 
chemical groups resonate at different frequencies and hence will have different chemical 
shifts. The vertical y-axis of the NMR spectrum gives the intensity of the resonance signal, 
proportional to the concentration of the sample analysed (Antcliffe and Gordon, 2016; 
Chatham and Blackban 2001; Wilson and Walker, 2010). Several types of NMR experiments 
have been developed to study various molecules. These include proton NMR (1H-NMR), 
carbon NMR (13C-NMR) and phosphorus NMR (31P-NMR). In a biological context, the basic 
applications of 1H-NMR, 13C-NMR and 31P-NMR are to detect groups of metabolites, identify 
bio-molecular structures (such as fatty acids carbohydrates and amino acids) and to analyse 
the biochemical processes that involve adenosine triphosphate (ATP) (Beckonert et al., 2007; 
Boyer, 2012). The use of NMR spectroscopy has grown tremendously over the years both in 
vitro and in vivo. NMR spectroscopy is widely applied in biological sciences (biomolecular 
structure determination, protein functions and interactions), metabolomics, pharmaceutical 
research (drug screening), medical sciences, food sciences and forensics (Hatzakis, 2019; Lu, 





Figure 2.6: A diagram representing the basic principles of NMR spectroscopy. When the sample is 
placed under the magnetic field in the NMR spectrometer, the spins in the protons of each molecule 
are either aligned with or against the direction of the external electromagnetic field (β0). Spin aligned 
with the magnetic field (α) has a lower energy state and are more stable than the spin aligned against 
the magnetic field (β). As the radio frequency energy is applied to the nuclei at lower energy state (α), 
the α spins are excited to higher (β) energy state. This excitation is short-lived and therefore the α 
spins return to a lower energy state after a very short period. The α spins emit radio frequency energy 
as they return to the lower energy state at different times. The emitted radio frequency energy is 
converted into free induction decay (FID), which is a time-domain signal. FIDs are processed and 
converted into a frequency domain spectrum by Fourier transformation and represented on the NMR 
spectrum as intensity vs. chemical shift (ppm) on the y-axis and x-axis, respectively. Abbreviations: ΔE: 
Change in energy; α: alpha; β: Beta; β0: External electromagnetic field; FID: Free induction decay; RF: 
Radio frequency 
 
2.4.6. The basic principle of mass spectrometry 
Despite the analytical strengths offered by NMR spectroscopy, MS has become a popular 
analytical platform in metabolomics due to its high sensitivity (Markley et al., 2017). The basis 
of MS involves ionisation of the molecules with subsequent measurement of mass to charge 
ratio (m/z) of the formed ions. This provides both qualitative and quantitative information 
concerning each molecule in a mixture (Urban, 2016). Mass spectrometers (the instruments 
used in mass spectrometry) consist of different components, each with a distinct function. 
The main components include the ion source, mass analyser, and a detector (Figure 2.7). 
Following the introduction of a sample mixture, containing the molecules of interest, in the 
ion source, the molecules are ionised to produce gaseous ions, which are transferred to a 
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mass analyser. The mass analyser sorts the ions based on their mass to charge ratio under the 
electric or magnetic field. These ions are then detected by an ion detector which determines 
the abundance of each ion. Subsequently, the ion detector produces electric signals which 
are processed and presented in a histogram called a mass spectrum; a function of m/z and 
relative abundance, on the x-axis and y-axis, respectively (Murayama et al., 2009; Patel et al., 
2012). Collectively, a mass spectrum represents the structure of the original molecules, the 
resulting fragments and any other species that may be formed during ionization (Urban, 
2016).   
Figure 2.7: Simplified (A) and detailed (B) schematic representations of the components of the mass 
spectrometer. Sample in the injector is delivered to the ion source where it is ionized into gaseous 
ions. The formed ions are sorted according to their m/z ratio in the mass analyser. The detector detects 
the electrical signal of each ion generated to give a mass spectrum. Adapted from Banerjee and 
Mazumdar, 2012 (A) and Antcliffe and Gordon, 2016 (B). 
 
Mass spectrometers are used as detectors hyphenated to chromatographic techniques such 
as gas chromatography (GC), and liquid chromatography (LC). Briefly, GC-MS deals with the 
separation of volatile and semi-volatile compounds using a high temperature and subsequent 
detection with MS (Sneddon et al., 2007). LC-MS, on the other hand, uses a liquid-based 
mobile phase, usually made of organic solvents and water, to separate different compounds 
in a mixture prior to ionisation and detection by MS. The coupling of MS with other 
techniques, particularly chromatographic techniques, enables the analysis of a wide range of 
molecules. MS has a wide range of applications in several fields including clinical studies, 
protein characterisation, drug discovery, quality control, food safety protocols, space 







2.4.7. Gas chromatography –mass spectrometry (GC-MS) 
The basis of GC-MS (Figure 2.8) is that volatile and semi-volatile compounds in a mixture are 
separated by GC and detected by MS. Separation of the compounds with GC is based on the 
partition of compounds in a mixture between the mobile phase and the stationary phase as 
the compounds pass through the column by the carrier gas (AL-Bukhaiti et al., 2017; Sneddon 
et al., 2007). Prior to GC-MS analysis, a sample containing a mixture of compounds is dissolved 
in a solvent such as methanol, acetone or heptane. The sample mixture is then delivered into 
the sample injector. The sample injector is placed in an oven to vaporise the sample upon 
injection (AL-Bukhaiti et al., 2017; Klee and Blumberg, 2002; Kupiec, 2004). The mobile phase 
carrier gas, as the name implies, carries the vaporised sample mixture through the column 
equipped with the stationary phase. The carrier gas is inert so that it does not react with the 
samples. Helium, nitrogen, argon or hydrogen are the most commonly used carrier gases, 
depending on the type of detector used (Hussain and Maqbool, 2014).  
A GC stationary phase comes in one of two available columns, namely, packed column or 
capillary (open tubular) column. In the former, the spherical stationary phase material is 
packed across the column tubing forming small sieves to allow the mobile phase to pass 
through. Some of the stationary phase materials used for packed columns include 
polyethylene glycols, methylphenyl- and methylvinylsilicone gums, apiezon L, succinic, 
phthalic acids and b-cyclodextrin-based phases for chiral separations (Wilson and Walker, 
2010). In capillary columns, the stationary phase is either a direct or indirect coat attached to 
the wall of the column, leaving an opening at the centre of the column. Hence, it is also called 
an open tubular column (Skoog et al., 2018). The capillary (open tubular) column functions on 
the principle of adsorption (Ye et al., 2000). Capillary columns are of two types, namely, wall-
coated open tubular (WCOT) and support-coated open tubular (SCOT), also called porous 
layer open tubular (PLOT).  WCOT differs from SCOT/ PLOT in that the stationary phase in 
WCOT is coated to the wall of the column whereas in SCOT/PLOT, the stationary phase is 
coated to a support (Skoog et al., 2018). 
As a mixture of compounds passes through the stationary phase, some compounds interact 
weakly with the stationary phase and elute from the column first. On the contrary, molecules 
that interact strongly with the stationary phase spend a longer time in the column and they 
have longer elution time (AL-Bukhaiti et al., 2017; Hussain and Maqbool 2014). In addition to 
these polarity-dependent interactions of the compounds and the stationary phase, 
temperature also determines the time spent by the compounds in the column. Thus, 
compounds with low boiling points elute first as compared to those with high boiling points 
(Oña-Ruales et al., 2016). Due to the crucial role that temperature plays in compound 
separation in a mixture, the column is placed in an oven so that the temperature can be 
controlled. The oven can be set to maintain a constant or gradually increasing temperature, 
known as ramping (Wilson et al., 2014). Ultimately, each compound in a mixture is eluted 
from the column at different elution times to be detected by the MS as described in Section 
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2.4.6. The GC-MS results are represented on a mass spectrum; a plot of m/z ratio and intensity 
on the x-axis and y-axis (Murayama et al., 2009; Patel et al., 2012). 
 
Figure 2.8: A diagram of GC-MS. From right to left, a mixture of compounds is injected into the GC 
through the sample inlet port. The mixture is vaporized prior to separation in the column, positioned 
in an oven. The mixture is separated based on the affinity of each compound to the stationary as well 
as the boiling point of each compound in a mixture. The separated compounds pass through the 
transfer line to the MS, where they are ionised for detection. The detected ions are represented on 
the mass spectrum.  
 
2.4.8. Two-dimensional gas chromatography (GC×GC) coupled with time-of-flight 
mass spectrometry (TOFMS) 
Although conventional GC provides a powerful separation technique, the complexity of many 
compounds exceeds the capacity of one-dimensional GC. To overcome this challenge, 
comprehensive two-dimensional gas chromatography (GC×GC) has been developed (Rocha 
et al., 2007; Tranchida et al., 2004). In GCxGC, sample separation is carried out using two 
separate columns with different polarities of the stationary phase (Kalinova et al., 2006; 
Spanik et al., 2012). The interface connecting the two columns, the modulator, is a cryogenic 
trap that condenses compounds as they elute from the primary column to the secondary 
column (Kalinova et al., 2006). The modulation process is essential as it increases the 
separation power and sensitivity (Dekeirsschieter et al., 2012; Patterson et al., 2011). Both 
separation potential and sensitivity are enhanced in two-dimensional GC×GC as compared to 
one dimensional GC (Zrostlıkova et al., 2003). The second column of the GCxGC is very short 
and can produce peaks as narrow as 0.1 s. This requires a detection system with high 
acquisition rates to properly describe each peak. Conventional MS can only acquire up to 50 
spectra s−1 and therefore it cannot properly detect all the peaks generated in GCxGC. As a 
result, the high-speed time-of-flight mass spectrometry (ToF-MS) has been developed with 
the capability to acquire up to 500 spectra s−1 (Kalinova et al., 2006; Rocha et al., 2007). ToF-
MS can detect a larger number of compounds in extreme complex mixtures, making ToF-MS 
the most effective GCxGC detector (Mohler et al., 2006). In general, GC×GC–ToF-MS provides 
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a powerful, sensitive and selective analytical technique for compound separation, detection 
and identification (Snow et al., 2010).  
Although the application of GC-MS is only limited to volatile and semi-volatile compounds, 
GC-MS is used in several fields. GC-MS has been shown to be capable of precise identification 
and quantification of an individual compound from a mixture. Secondly, GC-MS is capable of 
identifying traces of contaminants in research concerned with compound purification 
(Tumuluru et al., 2012). Hence GC-MS has gained popularity in fields such as food sciences 
(Hussain and Maqbool, 2014), forensics, environmental studies, beverage, geo-chemical and 
astro-chemistry research, medicine and pharmaceutical research, biological and pesticides 
detections, energy and fuel applications, industrial and academic research (as reviewed by Al-
Rubaye et al., 2017). 
 
2.4.9. Metabolomics statistical analysis  
Metabolomics analytical techniques generate high dimensional complex data, making it 
difficult to process and analyse the acquired data. The complexity of the data generated in 
metabolomics prompts the need for statistical methods that will be able to handle such data.  
Multivariate data analysis (MVDA) is used to statistically make sense of the generated data. 
MVDA is categorised into unsupervised and supervised methods. The unsupervised methods 
are usually the first statistical methods applied. These methods are called unsupervised 
simply because the data analysed are not assigned to class membership. Thus, prior 
knowledge about the data membership is not required (Ren et al., 2015).  Unsupervised 
methods can be categorised further into dimension reduction methods and cluster analysis 
methods. 
2.4.9.1. Unsupervised statistical methods 
Principal component analysis (PCA) remains the most commonly used dimension reduction 
method. This is an exploratory analysis method that reduces the complexity of high 
dimensional data by capturing the information that contributes to the observed variation. 
PCA reduces the dimensionality of the data set without the loss of core information (Gromski 
et al., 2015; Saccenti et al., 2014). Ultimately, PCA gives a summary of the data set, showing 
the within-group and between-groups variation in the given data set. The trend, grouping and 
outliers in the data set can also be seen in PCA modelling (Trygg et al., 2007). Cluster analysis 
methods, such as hierarchical cluster, seek to find a cluster of samples in multidimensional 
space with similar characteristics. The clustering of samples forms a tree-like structure called 




2.4.9.2. Supervised statistical methods 
In addition to unsupervised methods, supervised methods are used in metabolomics data 
analysis mainly for prediction, classification and biomarker discovery. Unlike unsupervised 
methods, supervised methods determine and explain the association between the predictors 
(X-data) and the categorical (e.g. disease vs. healthy) or quantitative (age, body mass index, 
sex, blood glucose) response variable (Y-data) in the data set (Ren et al., 2015). Commonly 
used supervised methods are based on partial least squares (PLS), which include projections 
to latent structures-discriminant analysis (PLS-DA) and orthogonal projections to latent 
structures–discriminant analysis (OPLS-DA). Whilst PLS-DA is widely used for the 
differentiation of classes in the data-set (Worley and Powers, 2013); its extension, OPLS-DA 
aims to maximize the differentiation of groups and identification of marker metabolites. 
These are metabolites responsible for differentiating the different groups in a data-set (Shin 
et al., 2011; Trygg et al., 2007). Another classic example of a supervised method, linear 
discriminant analysis (LDA), functions similarly to PCA in the manner that it projects a high 
dimensional dataset onto a lower dimensionality subspace (Kim and Yeom, 2017). LDA 
extracts, separates and classifies dataset, into groups with similar features, maximizing 
separation between-–groups covariance and minimizing separation within-–group covariance 
(Giraldi et al., 2008; Yeom et al., 2007).  
Although multivariate data analysis is the most important component in handling complex 
metabolomics data, univariate statistical methods are just as important since they allow 
metabolomics data features to be analysed independently. However, univariate methods do 
not account for interacting metabolomic features as opposed to multivariate data analysis 
and this is the main disadvantage of univariate statistical methods in metabolomics (Lazar et 
al., 2015). Univariate statistical methods are used for the reduction of a large number of 
measured features to those that only show the maximum variations between study groups in 
response to the investigated perturbation (Bartel et al., 2013). Among several univariate 
methods available, parametric tests, Student’s t-test and analysis of variance (ANOVA) are 
commonly used to analyse metabolomics features independently in a data-set (Alonso et al., 
2015). A probability value (p-value) is widely used to determine the statistical significance of 
the difference between two variables measured in, for example, cases and controls. By using 
a p-value, one can easily accept or reject the null hypothesis or alternative hypothesis (Vinaixa 
et al., 2012).  
 
2.4.10. Statistical validation 
Statistical data generated in MVDA require validation, mainly to assess their significance and 
reliability (Worley and Powers, 2013). In supervised methods, for instance, detection of many 
variables (metabolites) from a small sample size comes with the danger of model overfitting. 
Although an over-fitted model can show a very good performance, such a model might not 
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accurately predict a new set of data. As a result, such a model cannot be duplicated (Xi et al., 
2014). Two main approaches, test-set validation and cross-validation (CV), have been 
developed for multivariate model validation. The former uses a new separate dataset to 
validate the developed model whereas, in the latter, model validation is performed using the 
same dataset used to generate the original model (Trivedi and Iles, 2012). The cross-validation 
method can cope with a low sample number; hence it is usually the method of choice 
(Westerhuis et al., 2008). In cross-validation, the experimental dataset is separated into 
different groups, which are randomly used in different combinations to build a permuted 
model. The original model is then validated by comparing it to the permuted model to 
determine the predictive accuracy (Trivedi and Iles, 2012). 
Cross-validation is subdivided into two categories, namely internal and external cross-
validation. Whilst internal cross-validation deals with the selection of the number of latent 
variables and finds an optimal PLS-DA model, external cross-validation focuses on the 
measurement of the performance of the model (Xi et al., 2014). A matric Q2 is used to 
measure the predictive ability of the developed model, which is the ability of the model to 
accurately predict new data when applied to the model. Furthermore, parameter R2 (the 
goodness of fit) explains the amount of variation between groups explained by the model. 
Therefore, Q2 and R2 describe the quality of the model and their values range between 0 and 
1 (Shin et al., 2011). A model with good predictive ability is indicated by Q2 ≥ 0.5 (Lauri et al., 
2016), however, a model with Q2 ≥ 0.4 is also acceptable for biological studies (Westerhuis et 
al., 2008). The R2 value is always higher than the Q2 value for a good model (Sedghipour and 
Sadeghi-Bazargani, 2012). In addition to Q2 and R2, cross validated-analysis of variance (CV-
ANOVA) and area under the receiver operating characteristic (ROC) curve (AUROC) are used 
to validate the OPLS-DA models. CV-ANOVA assesses the significance (reliability) of the PLS-
DA and OPLS-DA models whereas the ROC curve validates the robustness and predictive 
performance of a model (Subramani et al., 2016). 
 
2.4.11. Metabolites annotation, pathways and network analysis 
Statistical analysis is followed by metabolite annotation, pathways and network analysis as 
well as the biological interpretation of the generated results. These are performed using a 
combination of available metabolomics software and databases. Identification of metabolites 
in human-based metabolomics can be done through various metabolomics databases such as 
Human Metabolome Database (HMBD), Biological Magnetic Resonance Data Bank (BMRB), 
Madison Metabolomics Consortium Database, Bayesil NMR Web App, MetaboMiner NMR 
command line lnterface and SpinAssign. Amongst these databases, HMDB is the commonly 
used database for human-based metabolites identification as it has more than 8000 verified 
entries (Aretz and Meierhofer, 2016). The identified metabolites are used to construct or 
identify relevant biological pathways to extract more useful biological information from the 
acquired data. Pathway analysis gives an overview and understanding of enzyme regulation 
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as well as post-translational modification of enzymes or proteins involved in metabolite 
synthesis (Nägele, 2014). The metabolism of an organism can further be explained by an 
alternative method, namely network analysis. A metabolic network gives information about 
the association and the interaction of genes, proteins and metabolites or small molecules 
(Kuhn et al., 2008). Kyoto Encyclopedia of Genes and Genomes (KEGG), which is a popular 
choice for pathway and network analysis, houses most biological pathways and networks that 
have been identified to date. KEGG biological pathways and networks are constructed on the 
basis of linking a set of genes with their interacting molecules to produce a network (Kanehisa 
and Goto, 2000). 
 
2.4.12. Biological interpretation of metabolomics data 
The major goal of any metabolomics experiment is to identify and understand the biological 
events that take place in a biological system under specific conditions. Accordingly, data 
acquired from a metabolomics experiment should correspond to the phenotype of the 
biological system of interest. There remains, however, a large knowledge gap in the 
translation of metabolomic data to biological interpretation (Scalbert et al., 2009). A single 
metabolite can participate in several metabolic processes, making it difficult to assign a 
metabolite detected in a metabolomics experiment to a single biological pathway. 
Nonetheless, the use of metabolomics tools/databases can provide sufficient information 
that could eventually lead to a true representation of the physiology of an organism or the 
biological question being investigated (Aretz and Meierhofer, 2016). Understanding 
metabolite up-regulation or down-regulation does not only provide insight into the biological 
pathways involved but also contains the information regarding the enzymes or other 
molecules involved in a metabolic pathway. Such information can be useful in determining 
the health status of an organism as well as the pharmacological action of a given treatment 
(Chagoyen and Pazos, 2012).  
 
2.4.13. Challenges in metabolomics 
Metabolomics has its challenges despite the advancement made over the past years. Firstly, 
various genetic and environmental stimuli can alter the metabolome of an organism. Care 
should therefore be taken during sample handling to obtain data that represent the true 
physiology of an organism (Johnson and Gonzalez, 2012). Secondly, some metabolites are 
identical across different species, which makes it difficult to study the metabolism of two 
interacting organisms (e.g. the interaction between the host and the pathogen). Thus, the 
host metabolome might not be differentiated from the pathogen’s metabolome (Schrimpe-
Rutledge et al., 2016).  Experimentally, metabolite extraction and data acquisition can also be 
challenging. In addition to biological and experimental related challenges, major challenges 
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are usually encountered in data processing, data visualisation, metabolite identification and 
validation (Bowler et al., 2017). Over the years, an effort has been made to overcome these 
challenges through the improvement of both analytical techniques as well as the statistical 
methods and software used in data handling (Steuer et al., 2019). 
 
2.4.14. Exploring 1,25(OH)2D3 metabolic impact through NMR and MS-based 
metabolomics 
 
Metabolomics has previously been applied in M.tb-related research, leading to the 
identification of TB biomarkers from various sample matrices (including M.tb culture, serum, 
plasma, lung tissue, spleen tissue) (Behrends et al., 2012; Dang et al., 2013; De Buck et al, 
2014; Feng et al., 2015; Frediani et al., 2014; Halouska et al., 2014 and Mahapatra et al., 2014). 
Tuberculostearic acid (TBSA), for example, is one of the most reliable TB biomarkers identified 
in metabolomics across various sample specimens (Du Preez et al., 2017). Through 
metabolomics, new metabolic processes, gene function, virulence factors and enzyme activity 
can be described to better understand the mechanism of the pathogen (Du Preez et al., 2019).  
Vitamin D has been closely related to improving the outcome of TB, however, a very limited 
amount of research has been conducted on understanding the metabolic effect of vitamin D 
during M.tb infection. Nonetheless, the association between vitamin D and M.tb infection has 
been described (Gibney et al., 2008). In their study, Gibney et al. (2008) reported that higher 
levels of vitamin D are associated with lower probability of M.tb infection and vice versa. 
Although vitamin D alone has not been clinically evaluated as a treatment for TB (Kearns, 
2014), the use of vitamin D with anti-TB drugs has been shown to accelerate the improvement 
of clinical outcomes of M.tb infection (Hassanein et al., 2016). This association has been less 
studied through metabolomics. As such, investigations are needed to understand the 
metabolic effect of vitamin D during mycobacterial infection. 
The metabolic effects of supplementary 1,25(OH)2D3 in vitro have been investigated in 
previous studies. A study by Santos et al. (2017) revealed that in vitro 1,25(OH)2D3 
supplementation in human embryonic kidney 293T (HEK293T) cells alters the cellular 
metabolic profile of the cells. Using NMR spectroscopy, Santos et al. (2017) found a slight 
increase in intracellular lactate concentration in HEK293T cells treated with 1,25(OH)2D3. An 
increase in lactate concentration is associated with up-regulation of glycolysis. Other 
metabolic pathways including the polyol pathway and Krebs cycle were down-regulated 
whereas phosphocholine pathway was up-regulated in the presence of 1,25(OH)2D3. In 
another in vitro study, Abu El Maaty et al. (2017) reported metabolic changes associated with 
in vitro 1,25(OH)2D3 supplementation. In their study, Abu El Maaty et al. (2017) supplemented 
different human prostate cancer (PCa) cell lines (LNCaP, VCaP, DU145 and PC3) with 
1,25(OH)2D3 prior to MS-based (GC-MS) metabolic profiling. The authors reported that the 
responsiveness of these cell lines to 1,25(OH)2D3 differs with LNCaP being the most responsive 
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cell line. In LNCaP cells, supplementary 1,25(OH)2D3 induced metabolic reprogramming of 
glucose metabolism, fatty acid metabolism, glutamine metabolism and tricarboxylic acid 
(TCA) cycle. Their study showed that 1,25(OH)2D3 has a metabolic impact on cellular 
metabolism.  
In a subsequent study, Abu El Maaty et al. (2018) supplemented breast cells (MCF-7 and MDA-
MB-231) with 1,25(OH)2D3. Using MS-based (GC-MS) metabolomics, the authors detected 
significant alterations in spectral regions associated with phosphoenolpyruvate, pyruvate, 
citrate, α-ketoglutarate, succinate, fumarate, malate, serine, glycine, L-alanine, proline, L-
leucine, isoleucine, threonine, aspartic acid, valine and glutamic acid. The authors further 
reported that supplementary 1,25(OH)2D3 induced energy metabolism reprogramming. It was 
shown in their study that 1,25(OH)2D3 induce reprogramming of the TCA cycle and the 
glycolytic pathway.   
Taken together, it is evident from these above-mentioned in vitro studies that 1,25(OH)2D3 
affects the metabolism of different cell types under different disease conditions, leading to 
metabolic reprogramming. Furthermore, these studies have shown that 1,25(OH)2D3 induced 
metabolic changes can be profiled using both NMR and MS-based metabolomics. Hence, the 
aim of the current study is to use NMR and MS-based metabolomics to determine the 
metabolic effect of 1,25(OH)2D3 supplementation in mycobacterial infection in vitro.  
 
2.5. The rationale behind using the in vitro system for the present study 
In vitro studies are dependent on the use of cell lines or models that resemble the in vivo 
systems of interest. Studying infectious pathogens comes with a high risk of being infected 
and therefore it requires a specialised and highly regulated laboratory with proper risk 
assessment (Patterson et al., 2014). Such requirements, however, come at a high cost. To 
overcome this, non-hazardous synthetic molecules that mimic molecules of interest are used. 
With the rapid growth of life sciences, the development and revolution of biotechnology in 
recent years, the in vitro approaches have become a cornerstone of basic research in many 
fields (Hartung and Daston, 2009). In metabolomics studies, the in vitro approaches provide 
a suitable system in the initial stages of biomarker discovery. Unlike the in vivo systems, the 
in vitro systems allow the investigator to strictly control the working environment. It further 
allows for accurate and strict control of the induction of the desired, specific variables being 
investigated. Furthermore, metabolomic studies concerned with pathogens performed in 
vitro, provide a clear insight into the pathogen metabolism since there is no host interfering 
metabolites. Such studies can be replicated easily with a high number of replicates at low 
costs. Despite the strengths that come with using the in vitro approach, the in vitro system 
has its pitfalls. Notably, the in vitro system does not account for the in vivo adaptation of the 
host or the microbe (Du Preez et al., 2019; Hartung and Daston, 2009). Also, the physiological 
relevance of the in vitro models differs from that of the in vivo systems. Cancer studies have 
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shown that in vitro studies only allow the investigator to capture limited aspects of the 
tumour microenvironment (Katt et al., 2016). Nonetheless, the in vitro models used in this 
study were the U937 cells as well as monocyte-macrophages.  
The U937 cell line is a monocytic, histiocytic lymphoma cell line originally isolated from a 37-
year-old Caucasian man. U937 cells are characterised by their oval shape with large, irregular 
shaped nuclei (Sundstrom and Nilsson, 1976). The popularity of the U937 cell line in research 
is due to its ability to resemble human macrophages, both morphologically and functionally 
(Mendoza-Coronel and Mastanon-Arreola, 2016). Some of these characteristics include the 
ability to perform antibody-induced cytotoxicity, phagocytosis of the pathogen and 
presentation of Fragment crystallizable (Fc) receptors that recognise subclasses of human IgG 
proteins (Alexander et al., 1979; Anderson and Abraham, 1980; Larrick et al., 1980). Human 
macrophages are terminally differentiated and non-dividing cells (Gordon and Taylor, 2005) 
and therefore cannot be isolated from the human body to be replicated for research in vitro. 
Hence, the U937 cell line provides a good in vitro model to study human macrophages. Several 
inducers including phorbol myristate acetate (PMA), retinoic acid (RA), interferon-Ƴ (IFN-Ƴ) 
and 1,25(OH)2D3 (Pagliara et al., 2005; Passmore et al., 2001) can differentiate U937 
monocytic cells to macrophages.  An additional strength of the U937 cell line is its ability to 
retain the monocyte-macrophage features for several years, making it possible for the cell 
line to be used for a long period at higher passage numbers (Chanput et al., 2015; Strefford 
et al., 2001). 
Monocytes-macrophages form an important component of the innate and adaptive immune 
response, immunomodulation, inflammation and tissue repair. Monocytes originate from 
haematopoietic stem cells through the common myeloid progenitor lineage. They are 
subdivided into three subsets—Classical (with marker CD14++CD16−), intermediate (CD14+(+) 
CD16+) and nonclassical (CD14+CD16++)—based on their function and surface marker they 
express (Ginhoux and Jung, 2014; Sprangers et al., 2016). Classical monocytes are the main 
subset in the immune response and phagocytosis. Monocytes are differentiated into 
macrophages and DCs. The functions of macrophages in the immune response have been 
categorised into antigen presentation, phagocytosis, and immunomodulation (Wynn et al., 
2013). Unlike monocytes, macrophages consist of ‘classical’ M1 and ‘alternative’ M2 
phenotypes that present proinflammatory and anti-inflammatory effects, respectively. 
Basically, M1 macrophages inhibit the pathogen whereas M2 maintains homeostasis to help 
repair and replace lost cells (Mills, 2012). Due to their pivotal roles in regulating the immune 
response and maintaining cellular homeostasis, macrophages are distributed throughout all 




2.6. Study rationale 
Previous studies have demonstrated that supplementary 1,25(OH)2D3 improves the immune 
response against M.tb infection; however, the effects of 1,25(OH)2D3 on the metabolism of 
immune cells responding to a mycobacterial infection remains elusive. Thus, the aim of the 
current in vitro study is to apply a multi-platfrom (NMR and GC-MS-based) metabolomics 
approach to elucidate differential metabolic changes related to the 1,25(OH)2D3-
supplementation in macrophages treated with mycobacterial elicitor to mimic infection. 
Although this is a preliminary study, it will provide necessary insights into the possible 
metabolic reprogramming events that define the effects of 1,25(OH)2D3 on the metabolism 
of macrophages responding to a mycobacterial infection. Understanding these metabolic 
events could be of importance towards determining how 1,25(OH)2D3 inhibits the activity of 
the mycobacteria in macrophages. Furthermore, the effectiveness of 1,25(OH)2D3 in the 
immune response against mycobacterial infection may be estimated or predicted. The 
workflow of the study is given in Figure 2.9. 
 
2.7. Hypothesis 
Untargeted metabolomics is generally considered a hypothesis-generating approach, where 
a new hypothesis could be derived from the initial findings (Goodacre et al., 2004). With that 
in mind, the accepted hypothesis for this study is as follows:  
“NMR and GC-MS-based metabolic profiling can detect metabolic changes induced by 
Pam3CSK4 stimulation of macrophages supplemented with or without 1,25(OH)2D3”.  
 
2.8. Research aim 
The main aim of this study was to evaluate the metabolic effects of 1,25(OH)2D3 on the 
metabolome of U937 macrophages stimulated with Pam3CSK4.   
2.9. Research objectives 
The specific objectives of the study are as follows: 
1. The first objective was to differentiate the U937 monocytes to macrophages through 
PMA induced treatment of monocytes. Microscopic assessments of differentiated 
U937 cellular morphology and flow cytometry analysis of CD14 surface markers of the 
monocyte/macrophage cell populations were performed to determine and confirm 




2. The second objective was to use NMR and GC×GC-TOFMS-based metabolomics, 
coupled with multivariate statistical analysis, to decode metabolic reprogramming 
induced by Pam3CSK4 stimulation, 1,25(OH)2D3 supplementation and a combination of 
both Pam3CSK4/1,25(OH)2D3 treatment in differentiated U937 cells. The metabolic 
profile of untreated (control) U937 macrophages were also determined.  
 
3. The third objective of the study was to determine the metabolic pathways affected by 
each treatment condition in order to evaluate the global metabolic reprogramming 





































2.10. Research workflow 
The experimental work was performed according to the workflow in Figure 2.9. 
 
Figure 2.9: Workflow of the study. The first step of the study was to culture U937 monocytes. Viable 
U937 monocytes were then differentiated to macrophages using PMA. Cellular differentiation was 
confirmed using microscopic assessments of morphology and flow cytometry analysis of CD14 surface 
markers of the monocyte/macrophage cell populations. Differentiated cells were treated with 
Pam3CSK4, 1.25(OH)2D3 and a combination of Pam3CSK4 and 1.25(OH)2D3 prior to 1H NMR spectroscopy 
and GC×GC-TOFMS metabolic profiling. The acquired data were subjected to univariate and 
multivariate statistical analysis. Statistical analysis was followed by metabolite annotation and 
pathway analysis. The last section of the study was the biological interpretation of the obtained 
metabolomics data. Abbreviations: 1.25(OH)2D3: 1,25-dihydroxyvitamin D3; CD14: Cluster of 
differentiation 14; GC×GC-TOFMS: Two-dimensional gas chromatography coupled with Time-of-flight 
mass spectrometry; NMR spectroscopy: Nuclear magnetic resonance spectroscopy; OPLS-DA: 
Orthogonal projections to latent structures–discriminant analysis; Pam3CSK4: Tripalmitoyl-S-glyceryl-
L-Cys-Ser-(Lys)4; PCA: Principal component analysis; PLS-DA: Projections to latent structures-




MATERIALS AND METHODS 
 
The following chapter (Chapter 3) consists of the materials and methods used in the current 
study. Some of the methods used were obtained from relevant published literature sources 
(Sellick et al., 2011) with some adjustments. The first two sections (Sections 3.1 and 3.2) 
present the methodology used for the culturing of U937 monocytic cells, which were 
subsequently differentiated into macrophages using PMA. The succeeding section (Section 
3.3) is divided into two sub-sections. The first sub-section (Section 3.3.1) presents the 
materials and methods used for microscopic assessment of monocyte to macrophage 
differentiation using a light microscope and the second sub-section (Section 3.3.2) consists of 
the methodology followed for flow cytometry-based measurement of surface maker 
differentiated cells. Sections 3.4 and 3.5 provide a descriptive explanation of the stimulation 
of U937 macrophages in the presence and absence of Pam3CSK4 as well as supplementation 
with or without 1,25(OH)2D3. This section is followed by the metabolic profiling of U937 
macrophages stimulated with Pam3CSK4, 1,25(OH)2D3 supplementation and a combination of 
both Pam3CSK4 and 1,25(OH)2D3 using a multiplatform metabolomics approach, involving 
NMR and GC-MS analytical systems (Sections 3.6 to Section 3.11). The last section of Chapter 
3 presents a detailed methodology on metabolic pathway analysis (Section 3.12). 
 
3.1. U937 monocyte culturing 
3.1.1. Method 
The U937 monocytic cell line was obtained from the American Type Culture Collection (ATCC, 
Virginia, United States). The U937 cells were cultured in Roswell Park Memorial Institute 
medium (RPMI) 1640 (Life technologies corporation, USA) supplemented with 30% fetal 
bovine serum (FBS) (GE healthcare life sciences, USA), 2 mM L-glutamine (LG) (Sigma-Aldrich, 
USA) and 1% (w/v) Penicillin-Streptomycin (Pen-Strep); 10 000 IU/mL Penicillin with 10 mg/mL 
Streptomycin, made up in 0.9% sodium chloride (NaCl) solution (Invitrogen, Waltham, MA). 
The cells were cultured at 37°C in a humidified atmosphere with 5% CO2.  Whilst the role of 
FBS in cell culture is to supply nutrients to the cells, L-glutamine alternatively provides energy 
for cell division. Pen-Strep is crucial for preventing the growth of microbes in the medium. 
After 24 hrs of incubation, the cells were centrifuged at 1000 xg for 1 min at room 
temperature to remove the culture medium. The obtained cell pellet was then cultured and 
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maintained in 1640 RPMI medium supplemented with 10% FBS, 2 mM L-glutamine and 1% 
(w/v) Penicillin-Streptomycin. The concentration of FBS was changed from 30% to 10% to 
obtain optimal cell growth. The culture medium was refreshed every 48 hrs until the cells 
reached 90% confluence. Cell counting was performed using trypan blue (Sigma-Aldrich, USA) 
on an automated cell counter. This was achieved by adding 20 µL of trypan blue to 20 µL of 
culture medium containg cells. The two solutions were mixed and 20 µL of the trypan blue-
culture medium was transferred to an automated cell counting slide. An automated cell 
counter was then used to count the cells.Upon achieving 90% cell confluence, 1 x 106 cells 
were plated in 35 mm diameter x 10 mm height cell culture dishes in 1640 RPMI containing 
10% FBS, 2 mM L-glutamine and 1% (w/v) Pen-Strep.  
 
3.2. Monocytes to macrophages differentiation 
3.2.1. Principle of the method 
The process of monocyte to macrophage differentiation involves both morphological and 
biochemical changes so that the differentiated cells can exhibit the properties and functions 
of the macrophages (Wallner et al., 2016). The reason for differentiating monocytes to 
macrophages is to study the response of macrophages following stimulation. Macrophages 
play a crucial role in the immune response. They are terminally differentiated and non-
dividing cells (Gordon and Taylor, 2005). For in vitro studies, macrophages are derived from 
monocytes. Monocytes-derived macrophages can proliferate in vitro and are long-lived. They 
also develop into specialised functions (Daigneault et al., 2010). Common inducers of 
macrophage differentiation are mentioned in Chapter 2 Section 2.6. In the current study, 
PMA was used to induce U937 monocytes differentiation to macrophages. The choice for 
using PMA was based on the findings from previous studies, where PMA was used successfully 
to differentiate U937 monocytes to macrophages (Mendoza-Coronel and Castañón-Arreola, 
2016; Passmore et al., 2001). A total of three replicates were included. 
3.2.2. Method 
Monocyte differentiation was achieved by exposing the U937 monocytes (1 x 106 cells/mL) to 
PMA (Sigma-Aldrich, USA) at the final concentration of 100 ng/mL dissolved in absolute 
ethanol. This final concentration was based on the previous findings of Yang et al. (2017) who, 
in their study, induced differentiation of U937 monocytes to macrophages using the same 
concentration (Yang et al., 2017). Although other compounds including tetradecanoyil-13-
phorbol acetate (TPA), dimethyl sulfoxide (DMSO), zinc (Zn2+), low concentration of glutamine 
and IFN-Ƴ can induce monocyte to macrophage differentiation, PMA has been shown to 
induce monocytes differentiation with high efficiency (Pagliara et al., 2005; Passmore et al., 
2001). Subsequent to PMA exposure, the cells were incubated for 24 hrs at 37°C in a 
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humidified atmosphere with 5% CO2 to allow the monocytes to fully differentiate to 
macrophages.   
3.3. Confirmation of monocytes to macrophage differentiation 
3.3.1. Microscope imaging 
3.3.1.1. Principle of the method 
Cellular activities that occur at a molecular level are reflected in the phenotype. The 
relationship between the molecular system state of a cell and its phenotype can thus be 
evaluated using microscopic analysis (Antony et al., 2013). Microscopic imaging of live cells 
reveals the information about the cellular structures, cellular dynamics and function (Frigault 
et al., 2009). These features can be observed in real-time and over a period of time, without 
necessarily changing the nature of the cell (Thorn, 2016). This imaging assessment is crucial 
for studying and understanding cellular differentiation (Loo et al., 2009; Watmuff et al., 2012; 
Zaretsky et al., 2012). Thus, in the current study, a light microscope was used to evaluate the 
morphology of U937 cells supplemented with or without PMA for 24 hrs. A total of three 
replicates were included. 
 
3.3.1.2. Method 
Monocyte to macrophage differentiation was first confirmed by performing the microscopic 
analysis of the U937 cells’ morphology. In this experiment, the morphology of the U937 
monocytic cells treated with PMA was compared with the morphology of the U937 monocytic 
cells that were not exposed to PMA. This was done to assess if there were any observable 
differences. The assessment was performed by treating 1x106 cells with PMA. The cells were 
then incubated for 24 hrs. At the end of the incubation period, the treated cells along with 
the control cells (untreated) were viewed on a Zeiss Axiovert 25 Phase Inverted light 
microscope using 40X magnification.  Following the visual assessment of the cells under the 
microscope, cellular micrographs were acquired using AxioVision 3.1 for further evaluation.  
 
3.3.2. Flow cytometry   
3.3.2.1. Principle of the method 
Changes in the physical properties of a cell such as size and granularity as well as molecular 
properties such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) content, gene 
expression, extracellular and intracellular receptors can all be quantified through flow 
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cytometry measurements (Betters, 2015). The basic principle of flow cytometry involves the 
measurement of the intensity of fluorescence which depends on the properties of the cells 
under investigation. The properties to be quantified are preselected using relevant flow 
cytometry dyes or monoclonal antibodies that are specific for either extracellular molecules 
or intracellular molecules of interest, depending on the staining procedure followed (Adan et 
al., 2017).  The components of a flow cytometer consist of fluidics, optics, electronics and a 
computer interface. The fluidic stream separates fluorochrome labelled cells into droplets 
each with a single cell (Betters, 2015; Jaye et al., 2012). The optical system consists of the light 
sources (laser of a specific wavelength), optical filters and mirrors that selectively direct the 
emitted wavelengths to the relevant detector. The electronics component consists of the 
photomultiplier tubes (PMTs) that generate electrical signals. The generated signal is then 
represented graphically, simultaneously as the forward scatter (FSC) on the x-axis and the 
side scatter (SSC) on the y-axis. FSC represents cell size while SSC represents granularity 
(Betters, 2015; Knijnenburg et al., 2011). 
 
3.3.2.2. Method 
Following the morphology evaluation, monocyte differentiation was quantified with a flow 
cytometry experiment by measuring the CD14 cell count. This experiment was carried out by 
first setting up an equal number of 35 mm diameter x 10 mm height cell culture dishes for 
positive and negative controls in triplicates. In each cell culture dish, 7 x 106 cells/mL were 
plated in 1640 RPMI medium supplemented with 200 mM LG, 10% FBS and 1% (w/v) Pen-
Strep. Cells used as a positive control were treated with 100 ng/mL PMA dissolved in absolute 
ethanol (Sigma-Aldrich, USA). Control cells were only treated with 4 µL of absolute ethanol 
(Sigma-Aldrich, USA). These cells were then incubated for 24 hrs. After the incubation period, 
cells were scraped from each culture dish with a rubber scraper before transferring into 15 
mL Falcon tubes. Cells were centrifuged at 500 xg for 10 min at room temperature and the 
supernatant was discarded. The cell pellets were resuspended in 1 mL of RPMI supplemented 
with 10% FBS. Cell count was performed using the trypan blue staining on an automated cell 
counter. For each condition, 1 x 106 cells/mL was added to a 96-well plate in triplicate. The 
RPMI medium was removed through centrifugation at 500 xg for 5 min at room temperature. 
Following the removal of the supernatant, cells were suspended and washed with 1x 
phosphate buffered saline (PBS), which was removed by centrifugation at 500 xg for 5 min at 
room temperature.   
Subsequently, the cell pellets were resuspended in 50 µL of a blocking solution made of 10% 
heat-inactivated human serum diluted in PBS and incubated for 1 min. The blocking solution, 
as the name implies, blocks the non-specific binding of the Fc receptors of the antibodies to 
prevent unintended antibody binding, which could lead to background fluorescence and 
subsequently, incorrect results (Andersen et al., 2016). The cells were then incubated for 1 
min at room temperature in the dark and then centrifuged at 500 xg for 5 min at room 
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temperature. The supernatant was discarded before adding a 50 µL fixation solution made of 
1,5 % paraformaldehyde (Sigma-Aldrich, St Loius, MO) in PBS to the pellets. Fixation is 
performed to preserve the cell structure and organelles (Viryasova et al., 2019). The 
resuspended pellets were incubated at room temperature for 30 min before the next round 
of centrifugation at 500 xg for 5 min at room temperature. After the supernatant was 
discarded, the pellet was resuspended in a 150 µL permeabilisation solution made of 0.2% 
Triton X in PBS. The permeabilisation solution partially destructs both cell and nuclear 
membrane. The significance of permeabilisation is to allow the antibodies to penetrate the 
cell for staining purposes (Viryasova et al., 2019). The mixture of the permeabilisation solution 
and the pellets was incubated for 15 min at room temperature. At the end of the incubation 
period, the suspended pellets were centrifuged at 800 xg for 8 min at room temperature. The 
supernatant was discarded leaving the pellets in the 96-well plate. All centrifugation steps 
were performed at room temperature.   
For CD14 labelling, the cell pellets were stained with primary and secondary antibodies. The 
primary antibody was anti-human CD14 immunoglobulin G2a (IgG2a) (Santa Cruz 
Biotechnology, Dallas, TX). The primary antibody solution was prepared by diluting 5 µL of 
anti-human IgG2a stock in 45 µL of 1% (w/v) bovine serum albumin (BSA)/PBS solution. The 
secondary antibody was a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG2a (Santa Cruz Biotechnology, Dallas, TX) secondary antibody. The solution of secondary 
antibody was prepared by diluting 1 µL of FITC-conjugated goat anti-mouse IgG2a stock with 
49 µL of 1% (w/v) BSA/PBS. The first step of CD14 labelling was performed by adding 50 µL of 
the primary antibody solution to the 96-well plate with the cell pellets and incubated for 30 
min at room temperature in the dark. Following the incubation period, 100 µL of the wash 
buffer (0.1% Triton X in PBS) was added to each well. The mixture was centrifuged at 800 xg 
for 8 min at room temperature. After discarding the supernatant, another 100 µL of the wash 
buffer was added to each well and another round of centrifugation was performed at 800 xg 
for 8 min. The supernatant was discarded. The pellets were resuspended in 50 µL of the 
secondary antibody before incubation for 30 min at room temperature in the dark. The 
samples were washed with 100 µL of the wash buffer and centrifuged for 8 min at 800 xg at 
room temperature after which the supernatant was discarded. Another 100 µL of the wash 
buffer was added to each well. Again, the suspended pellets were centrifuged at 800 xg for 8 
min at room temperature and the supernatant was discarded.  
For flow cytometry analysis, the pellets were resuspended in a 150 µL BSA/PBS solution. The 
resuspended cell pellets were transferred to the flow cytometry tubes. Another 150 µL 
BSA/PBS was added to the tubes to top up the solutions to a total volume of 300 µL solution 
in each of the flow cytometry tubes. The fluorescence of each sample was quantified within 
2 hrs on a BD FACS ARIA II flow cytometer (BD Bioscience) at an excitation wavelength of 406 
nm and emission of 450 nm (BD FACSDiva™ Software 6.1.3).  A total of three replicates were 




3.4. In vitro U937 stimulation with Pam3CSK4 and 1,25(OH)2D3 supplementation 
3.4.1. Principle of the method 
Pam3CSK4 is an agonist of TLR2/1 receptor that simulates bacterial stimulation and 
immunomodulatory effects towards bacterial lipoproteins (Aliprantis et al., 1999; Akira et al, 
2003). Pam3CSK4 also mimics the triacylated lipoprotein of mycobacteria (Yang et al., 2015).  
It is, therefore, expected that Pam3CSK4 will have an immunomodulatory effect similar to that 
induced by mycobacteria. It is for this reason that U937 macrophages were stimulated with 
Pam3CSK4 in the current study. The mechanism through which Pam3CSK4 induces the immune 
response is explained in detail in Chapter 2 Section 2.2.  Briefly, the binding and activation of 
TLR2/1 by Pam3CSK4 induce the expression of NF-kB. Subsequently, NF-kB expression favours 
the production of cytokines including TNF-α, IL-6 and IL-12. Furthermore, TLR2/1 activation 
initiates endocytosis of Pam3CSK4–TLR 2/1 complex via the activation of α1β1 integrin 
receptor. As a result, the concerned immune cell secretes IL-6 and type 1 interferon to signal 
neighbouring cells about the infection of the first cell.    
 
3.4.2. Method 
The following experiments were set up according to Figure 3.1. This includes the treatment 
of the U937 differentiated macrophages with or without Pam3CSK4 and supplementation with 




Figure 3.1: Experimental set up for differentiated U937 treatment. 
The U937 monocytes were first differentiated to macrophages with 100 ng/mL PMA for 24 hrs before 
stimulation with or without 6.5 µL Pam3CSK4. The cells were then supplemented with/without 
1,25(OH)2D3 for 12 hrs, 16 hrs or 24 hrs.   
 
As illustrated in Figure 3.1, Pam3CSK4 (EMC microcollections, Tuebingen, Germany) 
reconstituted in endotoxin-free water was used to stimulate the TLR2/1 of the macrophages. 
A final concentration of 6.5 µg Pam3CSK4/mL was used based on the findings of Meyer (2015), 
a previous PhD student from the same research group, who used this concentration to 
stimulate the immune response of the peripheral blood mononuclear cells (PBMCs). This was 
an optimal concentration after a series of Pam3CSK4 concentrations were evaluated. As per 
Figure 3.1, 1 x 106 U937 cells induced with 100 ng/mL PMA were stimulated with 6.5 µg 
Pam3CSK4/mL in triplicates for 12 hrs, 16 hrs and 24 hrs. In several studies, Pam3CSK4 was able 
to effectively induce the immune response in a 24 h incubation period. For instance, Weir and 
colleagues (2017) stimulated the expression of cell surface receptors in B cells with Pam3CSK4 
at a 24 hrs incubation period. Additionally, in their study, Al-Rashed et al. (2017) were also 
able to induce matrix metalloproteinase (MMP-9) in human monocytic THP-1 cells at 24 hrs. 
Based on the above-mentioned studies, 24 hrs was one of the chosen time points for the 
current study as there is enough evidence showing that Pam3CSK4 can induce immune 
response at this time point. Regardless of these findings, it has also been found that Pam3CSK4 
40 
 
can stimulate cells earlier than 24 hrs. In a study by Hellman et al. (2018), PBMCs were 
stimulated with Pam3CSK4 in a 12 hrs incubation. A 12 hrs incubation period was therefore 
also selected. Moreover, Lee et al. (2014), was able to stimulate BC2 cells at a 16 hrs 
incubation. Based on these studies, 3 incubation periods (12, 16, and 24 hrs) were used in the 
present study. Performing the experiment at three different time points was crucial in 
determining the effect of time in each experimental condition evaluated.  
 
3.5. U937 macrophages supplementation with 1,25(OH)2D3 
1,25(OH)2D3 is an important hormone with the ability to stimulate the immune response of 
the macrophages. To study the effect of 1,25(OH)2D3 in U937 macrophages, U937 cells 
stimulation with/without 6.5 µg Pam3CSK4/mL were supplemented with/without 10 nM 
1,25(OH)2D3 (Sigma Aldrich, St Louis, MO). The choice of using the final concentration of 10 
nM 1,25(OH)2D3 was based on published literature (Edfeldt et al. (2010); Liu et al. (2006); Liu 
et al. (2009)). In these studies, it was shown that 10 nM 1,25(OH)2D3 is sufficient to effectively 
induce the expression of VDR genes and thus increase VDR levels. Following 1,25(OH)2D3 the 
cells were incubated for 12 hrs, 16 hrs, and 24 hrs. At the end of each incubation period, the 
cells were prepared to study the metabolic effect of the aforementioned treatments on the 
cells. The treated cells were quenched for metabolic analysis as explained in the following 
section.  
 
3.6. Cell quenching 
3.6.1. Principle of the method 
It is crucial that the metabolic profile acquired in a metabolomic study is a true representation 
of the metabolism or metabolic profile of a cell at the time of metabolite extraction. Such can 
be achieved by quenching the cells before extracting the metabolites. Quenching is the 
process in which the metabolism of a cell is terminated by stopping all the cellular enzymatic 
activities to prevent undesired changes in composition and concentration of the metabolites 
to be extracted (De Koning and Van Dam, 1992; Faijes et al., 2007). Although several 
quenching methods have been published in the literature, only a few are efficient and highly 
reproducible. A good quenching method can be characterised by the following: (1) the ability 
to completely terminate and block cellular metabolism immediately when the quenching 
process is initiated; (2) not disruptive to the cellular membrane to prevent the leakage of 
intracellular metabolites; (3) ability to prevent the contamination of the sample of interest 
with undesired extracellular metabolites, and lastly (4) it should yield a metabolic profile that 
is a true representation of the cells’ physiology. Thus, it should not interfere with the 




For the NMR-based metabolomics approach, quenching was performed using liquid nitrogen. 
The advantage of using this quenching method lies in the fact that samples are frozen below 
−100°C, which allows an immediate termination of the metabolic processes. Liquid nitrogen 
allows quenching to be performed within a few seconds in a one-step procedure (Sellick et 
al., 2011). Quenching was performed after the specified incubation periods (12 hrs, 16 hrs 
and 24 hrs) were reached. Cells in culture dishes were gently scraped and transferred into 15 
mL falcon tubes and the tubes were centrifuged for 1 min at 1000 xg at −20°C to remove the 
growth medium. After discarding the supernatant, the cells (pellets) were snap-frozen in 
liquid nitrogen (−196°C) once.  The cells were then stored below -100°C. The frozen cells were 
allowed to thaw prior to the metabolite extraction.  
 
3.7. Intracellular metabolite extraction 
3.7.1. Principle of the NMR method 
Metabolite extraction is a critical pre-analytical step in metabolomics workflow, aiming to 
collect (often in a solution form) metabolites of interest from a biological system or matrix. 
The ideal metabolite extraction process should and would lead to a wide coverage of the 
metabolome under investigation (Lu et al., 2017). A successful metabolite extraction step is 
necessary in for metabolomics analysis as it drastically influences the outcomes of the 
experiment. Despite the ability of NMR spectroscopy to measure metabolites in the whole-
cell without extraction, more informative and quantitative measurements can only be 
achieved from the extracted metabolites (Cuperlović-Culf et al., 2010). Nonetheless, 
metabolite extraction remains challenging as there is no single extraction method that can 
extract all metabolites of a specimen. A single extraction method can only cover a group of 
metabolites with similar properties, e.g. polar vs. nonpolar, fatty acids or amino acids (Pinu et 
al., 2017; Cuperlović-Culf et al., 2010). To overcome this challenge, a combination of 
extraction methods is usually used to extract the largest number of metabolites from the 
specimen. For liquid-based extraction methods, common extraction solvents used include 
chloroform/methanol (De Koning and van Dam, 1992), cold methanol (De Jonge et al., 2012), 
hot water (Bolten et al., 2007) and methanol/water (Sellick et al., 2011), among others. In the 
current study, cold methanol/water extraction method was used for intracellular metabolite 
extraction according to the extraction method developed by Sellick et al. (2011), with minor 
modification. The combination of cold methanol and water has been shown to recover the 
maximum number and a large range of metabolites from suspension mammalian cells (Cao 
et al., 2011; Sellick et al., 2011; Shin et al., 2010). Keeping the sample temperature lower by 
using cold extraction solvents minimizes variability and achieves optimal stability of most 




Following cell quenching, the cell pellets were resuspended in 500 µL of 100% methanol at 
−80°C, transferred to a microcentrifuge tube (tube 1) and snap-frozen in liquid nitrogen. The 
use of 100% methanol at −80°C further ensures that no enzymatic reaction or metabolic 
processes occur during extraction. The frozen cells were thawed and vortexed for 30 s prior 
to a cycle of centrifugation at 800 xg for 1 min at room temperature. The resulting 
supernatant was pooled into a fresh microcentrifuge tube (tube 2) on cold ice. The cell pellet 
in tube 1 was resuspended in 500 μL of 100% methanol (−80°C), snap-frozen in liquid nitrogen, 
thawed and vortexed for 30 s. Again, contents in tube 1 were pelleted by centrifugation at 
800 xg for 1 min at room temperature and the supernatant was pooled into tube 2 on cold 
ice. The cell pellet in tube 1 was resuspended in 250 µL of Milli-Q water, snap-frozen in liquid 
nitrogen, thawed and vortexed for 30 s.  The cells were pelleted by centrifugation at 15000 
xg for 1 min at room temperature. The supernatant was pooled into tube 2 so that the final 
ratio of methanol to water in tube 2 was 1:0.25. The solution in tube 2 was centrifuged at 
15000 xg for 1 min at room temperature and the supernatant, pooled into a fresh tube (tube 
3) was dried in a centrifugal evaporator at 30°C for 2 hrs. The dried metabolite pellets were 
stored at −80°C until NMR spectroscopic analysis.  
 
3.8. NMR data acquisition 
3.8.1. Principle of the method 
The basis of NMR spectroscopy involves measuring the magnetic properties of the atomic 
nuclei that have different magnetic spins (protons) such as 1Hydrogen (1H) and 13Carbon (13C). 
A detailed principle of NMR spectroscopy is given in Chapter 2 Section 2.5.6. Briefly, during 
the NMR spectroscopy measurements, the sample of interest is placed in a magnetic field. 
Subsequently, the nuclei of each molecule will either align with or against the magnetic field. 
As the radio frequency energy is applied, only NMR-active nuclei will resonate, each at a 
unique, characteristic frequency. These frequencies are given as chemical shifts on the NMR 
spectrum relative to a reference signal (Antcliffe and Gordon, 2016; Howard, 1998; Wilson 
and Walker, 2010). 1H is the most abundant nucleus in almost all metabolites as compared to 
13C and 31P nuclei, making 1H easily visible by the NMR.  
 
3.8.2. Method 
In this study, all one dimensional (1D) 1H NMR spectra were acquired using TOPSPIN 3.2 
(Bruker, Biospin Germany) at 25°C on a Bruker Avance III 500 MHz NMR spectrometer 
(University of Johannesburg, Department of chemistry) operating at 500.13 MHz. The NMR 
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spectrometer was equipped with a double resonance broadband (BBI) probe. A 1D nuclear 
overhauser effect spectroscopy (NOESY)-presaturation sequence was used for water and 
solvent suppression. All 1D NOESY were acquired at 25°C with an acquisition time of 1.64 s, 
mixing time of 0.05 s, relaxation delay of 2 s and 128 scans collected with receiver gain of 203 
dB and a spectral width of 10 000 Hz (20 ppm). The obtained spectra were baseline corrected 
and phased.  The corrected spectra were referenced to the signal of TSP at δ 0.00 ppm and α-
glucose at δ 5.23 ppm. All processed spectra were subjected to AMIX-viewer 3.9.15 (Bruker 
Biospin, Germany) for segmentation into bins with an equal width of 0.04 ppm. The water 
region (δ 4.4-5.5 ppm) was excluded as this region potentially interferes with low molecular 
weight metabolite regions on the NMR spectrum.  The final binned data file was exported into 
a Microsoft Excel file 2013.  
 
3.9. Chemometric and multivariate data analysis 
3.9.1. Principle of the method 
In untargeted metabolomics studies, sample analyses generate complex and multivariate 
data, which requires advanced statistical and chemometrics methodologies to meaningfully 
handle and mine these obtained (information-rich) datasets. Both univariate and multivariate 
data statistical methods are often applied, enabling the extraction of relevant, meaningful 
information from these highly complex data with aim of providing biological knowledge on 
the question under investigation (Saccenti et al., 2014). When only one variable is statistically 
analyzed at a time, a so-called univariate statistical method is performed. The application of 
univariate statistical tests and analyses in a metabolomics context implies testing hundreds 
of metabolites, which subsequently requires imperatively correcting for multiple tests to 
avoid or minimize having false positives. A reflection on univariate statistical methods in 
metabolomics can be found in the cited literature herein (Saccenti, et al., 2014). It is worth 
noting that these univariate methods, such as t-test or ANOVA, allow to statistically assess 
one single variable (metabolite), which could contain biological information and description 
on the phenomenon under study (Saccenti et al., 2014; Vargason et al., 2017).  
On the other hand, MVDA, as discussed in Chapter 2 Section 2.5.11, is used to handle 
multivariate data generated in metabolomics data acquisition. MVDA methods are capable of 
examining multiple variables simultaneously to reveal the inherent structures and biological 
information contained in these multiple variables (Mengual-Macenlle et al., 2014). MVDA 
methodologies determine and quantify the relationships between variables, contained in the 
measured variation and expressed as covariation and/or correlation (Shiker, 2012). MVDA 
models are thus computed, capturing a fraction of this variation, with a certain level of 
prediction. The information contained in these models is then presented visually in the form 
of plots/graphs. In the current study, PCA, an unsupervised MDVA method, was used for 
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dimensionality reduction and data exploration. Such exploratory methods reveal data 
structures, pointing to (dis)similarities between and within sample groups, and highlighting 
thus sample clusters, trends and outliers (Biancolillo and Marini, 2018). To complement 
MVDA methods and extract more detailed information, a supervised MVDA method, OPLS-
DA, was applied. For more description on PCA and OPLS-DA, refer to Chapter 2 Section 2.5.11. 
Prior to constructing the MVDA models, data pre-treatments (e.g. sample and variable 
normalization and missing value imputation) are applied. Furthermore, in computing these 
multivariate models, tuning and validation procedures are mandatorily applied to ensure 
statistical significance, reliability and validity of the generated models (Westad and Marini, 
2015). Such validation procedures include permutation tests and CV. As mentioned in Chapter 
2 Section 2.5.12, the basis of CV involves the decomposition of the data matrix into validation 
and training subsets, and through different iterations, evaluating performance estimates, 
model bias and predictability (Trivedi and Iles, 2012).  
 
3.9.2. Method 
The AMIX-processed data (excel file) was exported to Soft Independent Modeling of Class 
Analogy (SIMCA) software package, version 15 (Umetrics, Sweden) for univariate and MVDA. 
The data was pareto scaled before computing PCA models. The strong outliers were assessed 
using the Hotelling’s T2 ellipse at a 95% confidence interval on a PCA scores scatter plot. 
Furthermore, moderate outliers were detected using distance to the model (DModX). The 
generated PCA models were tuned and validated by the 7-fold CV method. This was achieved 
by generating the squared Pearson correlation coefficient goodness of fit (R2) and predictive 
ability (Q2) values.  
In order to maximize and observe separations between the study groups, OPLS-DA modelling 
was performed. This is a supervised modelling which can be used to identify discriminant 
variables responsible for the separation between two classes, which can be useful for 
biomarker identification. The significance of each generated OPLS-DA model was assessed by 
generating the CV-ANOVA value for each model where a p-value of <0.05 represents a 
statistically good model. From the constructed OPLS-DA models, a loadings S-plot and variable 
importance plot (VIP) were generated to identify variables discriminating the study classes. 
Loadings S-plot is an S-shaped plot of modelled covariation and correlation, allowing to 
extract variables (metabolites) with high covariation (i.e. high magnitude) and high 
correlation (i.e. high reliability). These discriminating variables are thus visually found at the 
extreme ends of the loadings S-plot. A VIP scoring is a metric that summarizes the importance 
of each variable in driving the observed class separation. Variables with VIP values above 1 
contribute more than average to the model, i.e. the observed group separation/classification. 
The fold change (equivalent to the relative concentration) for each variable was also 
generated. Fold change values above 1 indicates an increase in the relative concentration 
while fold change below 1 indicate a decrease in relative concentration.  
45 
 
3.10. Metabolite annotation 
The identity of the metabolites associated with the variables differentiating the study groups, 
according to the loadings S-plot, were assigned using the chemical shift (ppm) values. These 
assignments were done using the Human Metabolome Database (HMDB) 
(http://www.hmdb.ca/)  and relevant published literature (Subramani et al., 2016; 
Govindaraju et al., 2000; Mickiewicz et al., 2014).  
 
3.11. Gas chromatography-mass spectrometry data acquisition 
Following the analysis of the 1H NMR data, it was found that the metabolic profiling of cells 
treated for 12 hrs yielded more potential signatory metabolites discriminating the study 
groups (which are, Pam3CSK4 stimulated cells, 1,25(OH)2D3 treated cells and cells 
supplemented with Pam3CSK4/1,25(OH)2D3). For the GC-MS analysis, the 12 hrs incubation 
was used as the time point for the analysis. The same protocols for U937 monocyte cell 
culture (Section 3.2.2), monocyte differentiation (Section 3.3.2), differentiation confirmation 
(Section 3.4), and in vitro U937 stimulation with Pam3CSK4 and 1,25(OH)2D3 supplementation 
(Section 3.5.2 and 3.6) were used prior to GC-MS analysis.  
 
3.11.1. Sample preparation and quenching 
The principle of quenching has already been mentioned in Section 3.7.1. At the end of a 12 
hrs incubation period, the RPMI growth medium was removed by spinning the cells at 1000 
xg for 1 min at room temperature. After discarding the supernatant (RPMI growth medium), 
the cells were washed twice with 2 mL ice-cold PBS (pH 7.4). Cells were washed by spinning 
the cells in PBS at 1000 xg for 1 min at room temperature. The resulting cell pellet was 
resuspended in 750 μL high performance liquid chromatography (HPLC) grade methanol 
(Sigma-Aldrich, St. Louis, MO). The mixture was then transferred into 2 ml Eppendorf safe-
lock tubes and the samples were stored at −80°C until analysis at the Centre for Human 
Metabolomics at the North West University.  The samples were delivered in dry ice. 
 
3.11.2. Metabolite extraction  
For the whole metabolome extraction, a single-phase extraction method proposed by Beukes 
et al. (2019) was applied to the experimental samples (1,5 million cells in 750 μL methanol), 
quality control (QC) sample aliquots and extraction blanks (750 μL methanol). A 50 μL internal 
standard (3-phenylbutyric acid), 250 μL chloroform, 250 μL H2O and a 3mm tungsten beads 
were added to each sample vial. The samples were then shaken in a vibration mill at 30 Hz for 
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5 min and centrifuged at 14 650 xg for 5 min. The supernatant was then transferred into a GC 
vial and dried under a gentle stream of nitrogen at 40°C for 20 min. Subsequently, 50 μL 
methoxyamine hydrogen chloride was added and the mixture was incubated at 50°C for 90 
min. This was then followed by the addition of 40 μL N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) (Sigma Aldrich, St. Louis, MO, USA) and 1% trimethylchlorosilane (TMCS) (Sigma 
Aldrich, St. Louis, MO, USA) to the vial. The vial was re-incubated at 60°C for 60 min. The 
extracts were then transferred to a 0.25 mL insert in a GC sample vial for analysis using GCxGC-
TOFMS.  
 
3.11.3. GCxGC-TOFMS analysis 
3.11.3.1. Principle of the method 
Detailed principle of GC-MS is given in Chapter 2 (Section 2.5.8). GC separates volatile and 
semi-volatile compounds in a mixture under high temperatures. The separated compounds, 
referred to as analytes, are then detected using MS. Before the GC-MS analysis, samples are 
dissolved in solvents such as acetone, methanol or heptane. The mixture is then injected to 
the GC, where it is vaporized under high temperature. The vaporized molecules are carried 
through the column by a carrier gas such as helium, hydrogen, nitrogen or argon (Sneddon et 
al., 2007; AL-Bukhaiti et al., 2017; Hussain and Maqbool, 2014). The vaporized analytes 
separate based on their differential affinity to the stationary phase coated on the column. 
The separated, vaporized analytes are then passed on to the mass spectrometer, where they 
are ionized. The formed ions are sorted in the mass analyzer and separated based on the mass 
to charge ratio. The separated ions are then detected by the ion detector in the MS, which 
produces electrical signals. The signals are represented in a histogram called mass spectrum 
as a function of m/z and relative abundance on the x-axis and y-axis, respectively (Murayama 
et al., 2009; Patel et al., 2012). In the current study, two-dimensional gas chromatography 
(GC×GC) coupled with time-of-flight mass spectrometry (TOFMS) was used for metabolic 
profiling. In GCxGC-TOFMS, sample separation is achieved using two separate GC columns 
(GCxGC) with different polarity of the stationary phase (Kalinova et al., 2006; Spanik et al., 
2012). The separated compounds in a sample mixture are subsequently carried to the TOFMS 
for detection. ToF-MS can detect up to 500 spectra s−1 (Kalinova et al., 2006; Rocha et al., 
2007). The detected compounds are represented in a mass spectrum. 
 
3.11.3.2. Method 
The GCxGC-TOFMS analysis was performed on a Pegasus 4D GCxGC-TOFMS (Leco 
Corporation, St. Joseph, MI, USA), using an Agilent 7890A GC (Agilent, Atlanta, GA) coupled 
to a time of flight mass spectrometer (Leco Corporation, St. Joseph, MI, USA) equipped with 
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a Gerstel Multi-Purpose Sampler (MPS) (Gerstel GmbH & co. KG, Eberhard-Gerstel- Platz 1, D-
45473 Mülheim an der Ruhr), equipped with a cryogenic cooler. The primary column was 
fused with Rxi-5Sil-MS phase. The length of the column was 30 m with an internal diameter 
of 0,25 mm with the film thickness of 0,25 μm. The secondary column was fused with the Rxi-
17 phase. The column was 1,400 m long with the internal diameter of 0,25 mm and the film 
thickness of 0,25 μm. Both columns were supplied by Restek (Bellafonte, PA, USA). The inlet 
was operated in a split ratio of 1:10 at 270°C with an injection volume of 1μl (derivatized 
sample). Helium (He) was used as a carrier gas at a constant flow of 1 mL/min. The 
temperature of the primary GC oven was initially programmed at 70°C for 2 min after which 
it was gradually increased at 4°C/min to a final temperature of 300°C, where it was 
maintained for 2 min. The temperature of the secondary GC oven was initially programmed 
at 85°C for 2 min. The temperature was then increased at 4.5°C/min to a final temperature of 
300°C with a 4.5 min hold. The modulator was programmed to have an initial temperature of 
100°C for 2 min. The temperature was then increased by 4°C/min to a final temperature of 
310°C with a 12 min hold. The effluent emerging from the primary column onto the secondary 
column was controlled using cryomodulation and a hot pulse of nitrogen gas of 0.5 s every 3 
s. For TOFMS, sample ionization was performed using electron ionization with 70 eV. The ion 
source temperature was kept constant at 200°C while the transfer line temperature was held 
at 270°C. The m/z was between 50–800 at an acquisition rate of 200 spectra/second after a 
350 s solvent delay. The detector voltage was programmed at 150 V offset.  
 
3.11.4. Peak identification and data matrix creation   
Peak identification and mass spectral deconvolution were performed using Leco Corporation 
ChromaTOF software (version 4.50) at an S/N ratio of 100, with a minimum of 3 apexing peaks. 
Peak identification was achieved using a level 3 identification according to Schymanski et al. 
(2014). The mass fragmentation patterns together with their respective GC retention times 
as generated by the MS were used to determine the identities of the peaks by comparing it 
to in-house and commercially available National Institute of Standards and Technology (NIST) 
spectral libraries (mainlib, replib).  
 
3.11.5. MVDA analysis  
Following peak alignment from the ChromaTOF software, peaks identified in the blank 
samples (system blanks and extraction blanks) were deleted from the dataset as these were 
considered to be contaminants. Compound areas were then normalised according to the total 
useful signal detected for each sample. The resulting dataset was subjected to MetaboAnalyst 
4.0 (https://www.metaboanalyst.ca/) for statistical analyses. The data was pareto scaled before 
analysis. Univariate statistics (student’s t-test and volcano plot) were used to identify features 
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that vary significantly between cells stimulated with Pam3CSK4, Pam3CSK4/1,25(OH)2D3 
supplemented cells and control cells (untreated). Furthermore, multivariate methods, PCA, 
PLS-DA and OPLS-DS were performed to extract more biologically meaningful information 
from the data. PCA was applied to reduce the dimensionality of the data and for data 
exploration. In addition, OPLS-DA was applied for binary classification analyses.  
 
3.12. Pathway analysis  
The annotated signatory metabolites from 1H NMR spectroscopy and GCxGC-TOFMS analysis 
were subjected to MetaboAnalyst version 4.0 (https://www.metaboanalyst.ca/) for 
metabolic pathway analysis. MetaboAnalyst allows the identification of metabolic pathways 
associated with the given metabolites. These are the metabolic pathways that are altered 
under the given conditions. Metabolic pathways were selected based on the level of 
significance with p<0.05 considered to be significant. These metabolic pathways contain most 


















The results generated in the study are presented in the current chapter. The first section 
(Section 4.1.) presents the results of U937 cellular differentiation. This section is divided into 
two sub-sections which consist of the results of the microscopic assessment of differentiated 
cells (Section 4.1.1) and flow cytometry-based measurement of surface maker differentiated 
cells (Section 4.1.2). The succeeding section (section 4.2) presents the results of the metabolic 
profiling of U937 macrophages stimulated with Pam3CSK4, 1,25(OH)2D3 supplementation and 
a combination of both Pam3CSK4 and 1,25(OH)2D3. This section is also divided into two sub-
sections: Nuclear magnetic resonance (NMR) spectroscopy-based metabolic profiling (Section 
4.2.1) and gas chromatography–mass spectrometry (GC-MS) based metabolic profiling 
(Section 4.2.2). The metabolic pathways associated with signatory metabolites identified in 
metabolic profiling are presented in Section 4.3., which is the last section of Chapter 4.  
 
4.1. Phorbol myristate acetate-induced cellular differentiation assessment 
4.1.1. Microscopic assessments of differentiated U937 cellular morphology 
The confirmation of PMA-induced monocytes to macrophage cellular differentiation was first 
performed by assessing the morphology of the U937 cells supplemented with or without 100 
ng/mL PMA for 24 hrs. The aim of this experiment was to evaluate if there are morphological 
differences between U937 cells cultured in the presence and absence of PMA. At the end of 
the incubation period (24 hrs), the morphological changes of the cells were examined using 
an inverted light microscope under 40X magnification. Cells cultured in the absence of PMA 
(Figure 4.1A) were shiny and round in shape with smooth edges, a typical morphology of U937 
monocytic cells (Shu et al., 2013; Zamani et al., 2013). On the contrary, PMA-treated cells 
(Figure 4.1B) showed a differential irregular cellular shape, with an elongation, rough edges 
and pseudopods. This PMA-induced cellular shape resembles an adhesion morphology of 




Figure 4.1: Cellular morphology assessment under the microscope: Micrographs of U937 cells 
supplemented without (A) or with PMA (B) for 24-hrs treatment. The micrographs show the 
differences in the morphology of cells between the two conditions. In the absence of PMA, cells are 
round in shape and have smooth edges. On the contrary, PMA supplemented cells have uneven, 
irregular shape with rough edges. Cells were viewed under 40X magnification on a Zeiss Axiovert 25 
Phase Inverted light microscope before the micrographs were acquired using AxioVision 3.1.  
 
 4.1.2. Flow cytometry analysis of CD14 surface markers of the 
monocyte/macrophage cell populations 
Cellular differentiation of monocytes to macrophages was also evaluated by measuring the 
level of the expressed surface marker CD14 on the U937 cells, following a 24 hrs incubation 
in the presence or the absence of 100 ng/mL PMA. Cells were stained with anti-human IgG2a 
primary antibody and a FITC-conjugated goat anti-mouse IgG2a secondary antibody. The flow 
cytometry analysis enabled the observation of whether treatment of U937 cells with PMA 
induced the expression of CD14 surface marker — a maker of monocyte to macrophage 
differentiation. Figure 4.2A illustrates the forward scatter (FSC-A) and the side scatter (SSC-
A) properties of the cell population. The FSC-A and SSC-A measure the size and granularity or 
density of the cell. The gate P1 on Figure 4.2B represents the U937 cells that abundantly 
expressed CD14 surface markers. The gate P1 confirms that the majority of the U937 cells in 
the measured population expressed CD14 cells. The quantification of CD14 count between 
PMA-treated and the control (untreated) cells showed that PMA-supplemented cells 
expressed a high-levels of CD14 as compared to the control cells (Figure 4.3). PMA 





Figure 4.2: Flow cytometry analysis of monocyte-macrophage CD14 count. (A) A dot plot provides 
the forward scatter (FSC-A) which is the measure of the size of cells and the side scatter (SSC-A), the 
granularity or density of the cell. (B) A histogram of CD14 labelled monocyte-macrophage cell 




Figure 4.3: Flow cytometry CD14 count. CD14 count of U937 cells supplemented with 100 ng/mL PMA 
vs. control cells incubated for 24 hrs. Each error bar represents the standard deviation. The two groups 
show statistically significant differences in CD414 counts, with p<0.001 ***. 
 
4.2. Multiplatform metabolic profiling of U937 macrophages treated with Pam3CSK4, 
1,25(OH)2D3 and a combination of both Pam3CSK4 and 1,25(OH)2D3 
To decode metabolic reprogramming induced by Pam3CSK4 stimulation, 1,25(OH)2D3 
supplementation and a combination of both Pam3CSK4/1,25(OH)2D3 treatment in 
differentiated U937 cells, NMR spectroscopy and GC-MS platforms were used in an 
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untargeted approach. For NMR spectroscopy analysis, proton (1H) NMR spectroscopy was 
used to detect the extracted metabolites. In addition to 1H NMR spectroscopy, GCxGC–TOFMS 
was used as a complimentary technique to expand the metabolome coverage. The results of 
these metabolic analyses are presented in the following sub-sections: Section 4.2.1 for NMR 
spectroscopy analysis and Section 4.2.2 for GC-MS-based metabolic profiling.  
4.2.1. NMR-based metabolic profiling of U937 cells treated with Pam3CSK4, 
1,25(OH)2D3 and a combination of both Pam3CSK4 and 1,25(OH)2D3 
 
The extracted metabolites of cells treated with Pam3CSK4, 1,25(OH)2D3, a combination of both 
Pam3CSK4 and 1,25(OH)2D3, as well as that of untreated cells, were analysed using 1H NMR 
spectroscopy. To monitor the changes over time, the treated cells were incubated for 12 
(Figure 4.4), 16 (Figure A1) and 24 hrs (Figure A2). Visually, treatment-related differences in 
the overlaid spectra were observed (Figure 4.4) and these included the presence or absence 
of peaks and changes in peak intensities. Furthermore, to adequately extract information 
from these spectral data, chemometrics methods were applied. Unsupervised modelling, 
particularly PCA, was applied for dimensionality reduction and data exploration. Furthermore, 
the supervised OPLS-DA was carried out for binary classification analyses. 
 
Figure 4.4: Representative overlaid 1H NMR spectra acquired using a 500 MHz Bruker NMR 
spectrometer (12-hrs treatment). The spectra represent the metabolic profiling of (A) control cells 
(untreated), (B) Pam3CSK4 stimulated cells, (C) 1,25(OH)2D3 treated cells and (D) 
Pam3CSK4/1,25(OH)2D3 supplemented cells. The labelled peaks are signatory metabolites identified 
from the Human Metabolome Database (HMDB) (http://www.hmdb.ca/) and relevant published 
literature (Govindaraju et al., 2000; Mickiewicz et al., 2014; Subramani et al., 2016). All spectra were 
referenced to TSP at δ 0.0 ppm and α-glucose at δ 5.53 ppm. 1,25(OH)2D3: 1,25-dihydroxyvitamin D3; 
AMP: Adenosine monophosphate. 
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4.2.1.1. PCA-based data exploration: Hidden internal data structures and sample 
groupings 
PCA revealed the between-group and within-group variation, the trend and outliers as 
depicted in Figures 4.5, Figure A3 and A4. Using the first two principal components, 
treatment-related sample grouping of control (untreated) cells, Pam3CSK4 and 1,25(OH)2D3 
treated cells can be evidently seen in scores space, even though there is some sample overlap 
(Figures 4.5A, A3A and 4A). Furthermore, Hotelling's T2 at 95% confidence level was used to 
detect strong outliers; and there were no strong outliers, i.e. there is no observation that is 
found outside the ellipse of scores scatter plots (Figures 4.5A, A3A and 4A). Distance to the 
model (DModX) was also computed to visually assess moderate outliers. The latter are 
observations with a value greater than the critical value denoted DCrit (0.05) (red dotted line) 
on the DModX infographics (Figure 4.5B and Figure A3B and A4B for 12, 16, and 24 hrs 
treatment, respectively); however, these outliers had no variable(s) with critical deviation 
from the rest of the dataset, hence they were retained. To further investigate the sample 
grouping revealed by PCA modelling, a supervised binary classification, OPLS-DA, was applied, 






Figure 4.5: PCA modelling. (A) PCA scores scatter plot showing sample grouping of control cells 
(untreated), Pam (Pam3CSK4), VitD (1.25(OH)2D3), and Pam3CSK4/Vit D (Pam3CSK4/1.25(OH)2D3) 
treated cells without any strong outliers as per Hotelling's T2 (95% confidence level). Component t[1] 
shows the between-groups variation and t[2] shows the within-group variation. The description of the 
computed PCA model are R2= 0.997, Q2= 0.969, components = 13. (B) DModX shows four moderate 
outliers with DModX values greater than critical value, DCrit (0.05) (red dotted line). 
 
4.2.1.2. Sample classification and variable selection — OPLS-DA modelling 
Supervised multivariate modelling, OPLS-DA, was performed to maximize the separation 
between the sample classes. This OPLS-DA binary classification and sample discrimination 
modelling allow for the extraction of more detailed and descriptive information from the 
dataset. Different OPLS-DA models were thus computed investigating the following classes: 
the control cells vs. Pam3CSK4 (Figure 4.6A), control cells vs. 1,25(OH)2D3 (Figure 4.6C), and 
control cells vs. Pam3CSK4/1,25(OH)2D3 (Figure 4.6E) for 12 hrs treatment. The OPLS-DA 
modelling infographs for the 16 and 24 hrs treatment is given in Figure A5 and A6, 
respectively. A clear separation was observed between the aforementioned classes, 
indicating that there were differences in the metabolome of the experimental groups 
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compared. A seven-fold CV procedure was applied as a tuning method in building the models; 
and the quality of each OPLS-DA model was assessed by inspecting R2X (the explained 
variation of the X variable by the model) and R2Y (the explained variation of the Y variable by 
the model), as well as the predictive ability of the model, Q2.  Generally, the metrics Q2 with a 
minimum value of 0.05 (50%) and R2 close to 1 are desirable as indicative of valid models 
(Triba et al., 2015). However, in practice, it is not possible to set a general limit for good 
predictability (Q2) since this strongly depends on the properties of the dataset, such as the 
number of observations included. Q2 of 0.04 (40%) or below can be accepted and have been 
published (Cai et al., 2012; Dong et al., 2013). Such models with poor predictability are further 
validated by other methods such as a permutation test. In this study, in addition to k-fold CV 
metrics (R2 and Q2), permutation tests were applied and the statistical reliability of the models 
was assessed using cross validated-analysis of variance (CV-ANOVA) by generating the 
probability (p) value with a cut-off value of p<0.05, which indicates a statistically significant 
model. All models met these validation requirements.  
For the selection of discriminant variables responsible for class separation, the OPLS-DA 
loadings S-plot for each model were generated and evaluated (Figure 4.6B, 4.6D and 4.6F, 
respectively). The discriminant variables are those located at the extreme ends of the S-plot 
(bottom left and top right). These are the variables that are significantly different between 
the classes. Such variables have a high correlation and covariation in a multivariate space and 
have a p<0.05. The selected variables were annotated by using the Human Metabolome 
Database (HMDB) (http://www.hmdb.ca/) and relevant published literature (Govindaraju et 
al., 2000; Mickiewicz et al., 2014; Subramani et al., 2016). The confidence in metabolite 
annotation was level 2, as classified by the current metrics of the Metabolomics Standard 
Initiative (MSI) (Sumner et al., 2007). The selected and annotated potential signatory 







Figure 4.6: OPLS-DA modelling and variable selection. An OPLS-DA model separating control cells vs. 
Pam3CSK4 (1+4+0 components, R
2
X = 0.989, R
2
Y = 0.995, Q
2
 = 0.99, CV-ANOVA p-value = 4.87 × 10−8) 
(A) the scores scatter plot of t1 vs. t1o, a window in the X space displaying the separation of the two 
classes in horizontal (t1) direction; and orthogonal variation or within-class variability (i.e., unrelated 
to the discrimination between the two classes) is expressed in the vertical (to[1]) direction. (B) the 
loading S-plot, a predictive component loading, which displays discriminant variables – the variables 
that are situated in the extreme ends of the loadings S-plot are statistically relevant and represent 
prime candidates as discriminating variables. (C) An OPLS-DA scores scatter plot separating the 
control cells vs. VitD (1,25(OH)2D3) supplemented cells (Components: 1+5+0, R2X= 0.993, R2Y= 0.998, 
Q2= 0.99, CV-ANOVA p-value = 4.1535 × 10-06); and (D) the loading S-plot displaying discriminant 
variables. (E) An OPLS-DA scores scatter plot and (F) the loading S-plot of Control vs. 
Pam3CSK4/1,25(OH)2D3. A clear separation can be seen between the two classes (1+3+0 components, 




Table 4.1: OPLS-DA-derived signatory metabolites discriminating between controls (untreated) and cells treated with Pam3CSK4, 1,25(OH)2D3 and a combination 












12 hrs 16 hrs 24 hrs 
Pam3CSK4 1,25(OH)2D3 Pam3CSK4/ 
1,25(OH)2D3 
Pam3CSK4 1,25(OH)2D3 Pam3CSK4/ 
1,25(OH)2D3 

































3.85 Methionine 0.899 0.049 — — 0.891 0.006 — — — — 0.813 0.003 — — 0.871 0.166 — — 
3.69 Galactose 1.190 0.008 — — 1.109 0.100 — — 0.916 0.379 0.840 0.018 0.728 0.024 0.788 0.013 0.786 0.030 
3.61 Myoinositol 0.612 4.15 x 
10−7  
0.459 0.0001 0.802 0.017 0.677 0.235 1.021 0.923 0.902 0.738 1.331 0.262 1.311 0.295 1.214 0.410 
3.57 Threonine/ 
glycine 
2 0.001 4.351 0.003 1.879 0.047 1.480 0.265 1.171 0.499 1.377 0.473 0.687 0.251 0.863 0.653 0.623 0.235 
3.53 Beta-glucose 0.807 0.0002 1.070 0.248 0.962 0.340 0.993 0.803 0.987 0.881 1.159 0.089 0.959 0.433 1.078 0.237 0.915 0.195 
3.21 o-Phosphocholine 0.920 0.009 0.744 0.008 0.604 7.13 x 
10−8  
0.914 0.342 0.762 0.016 0.828 0.049 1.084 0.666 0.886 0.479 — — 
2.25 Valine 2.463 2.04 x 
10−5  
— — — — — — — — — — 1.394 0.289 — — — — 
1.33 Lactate 1.143 0.117 1.144 0.118 — — 1.045 0.444 0.957 0.397 0.912 0.209 1.061 0.461 1.004 0.963 1.339 0.006 
3.65 Mannose — — 1.419 0.0003 1.290 0.011 1.162 0.011 — — 0.741 0.033 1.203 0.158 — — — — 





















— — 1.262 0.056 
3.77 Ornithine/ 
glycerol 
— — — — 0.863 0.021 — — — — 0.788 0.0008 — — — — — — 
2.41 Succinate — — — — 1.123 0.051 — — 0.889 0.161 — — — — 0.838 0.003 — — 
3.97 Tyrosine/ 
Phenylalanine  
—     —      — — — — — — — — — — 1.374 0.024 — — — — 
2.45 Glutamate — — — — 1.111 0.013 — — — — — — — — 0.834 0.002 — — 
0.97 Leucine  — — — — — — — — — — — — — — 0.875 0.006 — — 
4.17 Pyroglutamate — — — — 0.748 0.008 — — — — — — — — — — — — 
2.97 Glutathione — — — — 0.747 0.001 — — — — — — — — — — — — 
2.53 Beta-Alanine — — — — 0.850 0.0004 — — — — — — — — — — — — 
2.17 Glutamine — — — — 0.817 9.82 x 
10−5 




As it can be seen in Table 4.1 and depicted in Figure 4.7, the discriminatory metabolites, which 
are biologically potential markers for the specific treatment in consideration, were up- or 
down-regulated. Furthermore, these metabolites were either unique to a treatment or 
overlapped. Their relative concentrations differ between the 12, 16 and 24 hrs treatment, 
indicating the changes in metabolic activities of the treated cells overtime. The identified 
discriminatory metabolites are members of different chemical classes including amino acids, 
carbohydrates, organic compounds and antioxidants.   
 
 
Figure 4.7: Graphical representation of potential signatory metabolites differentiating Pam3CSK4 
stimulation, 1,25(OH)2D3 treatment and Pam3CSK4/1,25(OH)2D3 supplementation at three time 
points. Figure 4.7 A, B and C show the signatory metabolites resulting from the metabolic profiling of 
the treated U937 cells treated for 12-, 16- and 24 hrs. Fold change value above 1 represents an 
increase in the relative concentration of metabolite whereas fold change value below 1 represents a 






4.2.2. GS-MS–mass spectrometry based metabolic profiling of U937 cells treated 
with Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 1,25(OH)2D3 
 
For GCxGC-TOFMS metabolic profiling, U937 differentiated cells treated with Pam3CSK4 or a 
combination of both Pam3CSK4 and 1,25(OH)2D3 were incubated for 12 hrs only. The choice of 
incubating the treated cells for 12 hrs was motivated by the 1H NMR spectroscopy analysis 
results. Meaning, in the 1H NMR spectroscopy analysis, more potential signatory metabolites 
were identified from the metabolic profiling of cells incubated for 12 hrs in comparison to 16 
and 24 hrs (Figure 4.7). Data generated from GCxGC-TOFMS metabolic profiling was subjected 
to both univariate and multivariate data analysis. For univariate statistical analysis, student’s 
t-test was performed to determine the features (metabolites) that are significantly different 
between control cells vs. Pam3CSK4; and control cells vs. Pam3CSK4/1,25(OH)2D3 (Figure 4.8). 
Furthermore, volcano plots of control vs. Pam3CSK4; and that of control cells vs. 
Pam3CSK4/1,25(OH)2D3 (Figure A7A and A7B, respectively) were generated to identify 
significant features (metabolites) discriminating the aforementioned groups. Significant 
features that are highly altered between the groups are those located far from the origin of 
the volcano plot at the far right or left. These metabolites, together with their fold changes 
and p-value are tabulated in Table 4.2.  
Thereafter multivariate methods, PCA, PLS-DA and OPLS-DA modelling were performed. PCA 
was performed to explore the internal structure of the GCxGC-TOFMS spectral data. The 
between-group and within-group variation was also revealed (Figure A8). To further extract 
descriptive information from the dataset, PLS-DA (Figure A9) was performed for sample 
classification and discrimination between the aforementioned groups. The generated PLS-DA 
scores models of both control cells vs. Pam3CSK4 (Figure A9A); and control cells vs. 
Pam3CSK4/1,25(OH)2D3 (Figure A9B) were not at all predictive, as indicated by a low or 
negative predictivity (Q2) value. Hence, OPLS-DA modelling was performed to maximize 
separation between classes. The generated OPLS-DA scores models (Figure A11A and A11B) 
were also not predictive. The OPLS-DA models were further validated using a permutation 
test. However, the predictivity of each model remained as a negative value, showing that the 
models are not predictive. Therefore, the only features (metabolites) that were considered 
to be significant from PLS-DA VIP scores (Figure A10) and OPLS-DA loadings S-plot (Figure 
A11C and 11D) are those that were identified by univariate statistics (Figure 4.8 (Generated 





4.2.2.1. Boxplot representing the relative abundance of metabolites between control 
cells vs. Pam3CSK4 stimulated cells and control cells vs. Pam3CSK4/1,25(OH)2D3 
supplemented cells 
GCxGC-TOFMS detected metabolites that are significantly altered between control cells vs. 
Pam3CSK4 stimulated cells, and control cells vs. Pam3CSK4/1,25(OH)2D3 supplemented cells as 
determined by the student’s t-test are shown in Figure 4.8. The box plots show the 
distribution of the potential marker metabolite between the aforementioned groups. These 
metabolites belong to chemical classes including fatty acids, amino acids, organic and 
inorganic compounds.   
 
Figure 4.8: Box plots of significant metabolites identified by t-test. These are metabolites that 
significantly contribute to the variance between (A) control cells vs. Pam3CSK4 stimulated cells, and 
(B) control cells vs. Pam3CSK4/1,25(OH)2D3 supplemented cells. The relative concentrations of these 
metabolites differ significantly between the experimental groups. Abbreviations: C: Control; PAM: 
Pam3CSK4; PD: Pam3CSK4/1,25(OH)2D3. 
 
Table 4.2: Signatory metabolites discriminating U937 macrophages cells stimulated with Pam3CSK4 
and those supplemented with a combination of both Pam3CSK4 and 1,25(OH)2D3 detected using 
GCxGC-TOFMS. These are important metabolites selected by the volcano plot. 
 
Metabolite 
Control vs. Pam3CSK4 Control vs. Pam3CSK4/1,25(OH)2D3 




0.054542 2.9986 x 10-5 0.12252 0.0006246 
Taurine - - 20.396 0.086935 
Niacinamide 11.084 0.027165 - - 
Unknown - - 4.7544 0.083741 
Unknown 0.34438 0.038087 - - 
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4.3. Analysis of metabolic pathways associated with the treatment of differentiated 
U937 cells with Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 
1,25(OH)2D3 
Metabolic pathways associated with signatory metabolites identified from 1H NMR 
spectroscopy analysis (12 hrs treatment) and GCxGC-TOFMS analysis are given in Figure 4.9. 
The labelled metabolic pathways are the most significant pathways with the highest hits (the 
actual number of metabolites matched from the uploaded data) (Table A1). 
 
 
Figure 4.9: Topology analysis of metabolic pathways affected in control cells vs. Pam3CSK4 
stimulated cells; control cells vs. and 1,25(OH)2D3, and control cells vs. Pam3CSK4/1,25(OH)2D3 
supplemented U937 macrophages. The pathway analysis is based on Kyoto Encyclopedia of Genes 
and Genome (KEGG) and was generated from MetaboAnalsyt 4.0. using metabolites that were 
significantly altered in the aforementioned study groups. Each circle represents a metabolic pathway. 
The size and the colour of the cycle reflect the pathway impact and p-value, respectively. Pathways 
with greater pathway impact are represented with bigger cycles. Dark red cycles represent metabolic 




Metabolic pathway analysis was performed to identify the metabolic reprogramming induced 
by U937 macrophage treatment with Pam3CSK4, 1,25(OH)2D3 or a combination of both 
Pam3CSK4 and 1,25(OH)2D3. The metabolic pathway analysis gives a snapshot of the 
metabolism of the U937 macrophages associated with the aforementioned treatment. 
 
In summary, the results clearly illustrate that PMA induced U937 monocytes to macrophage 
differentiation as determined using macroscopic analysis of U937 cells treated with or 
without PMA (Section 4.1.1). Flow cytometry analysis of CD14 surface markers of the 
monocyte/macrophage cell populations further confirms that U937 monocytes treated with 
PMA were differentiated to macrophages (Section 4.1.2). Metabolic profiling differentiated 
cells treated with Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 
1,25(OH)2D3 (Section 4.2) illustrated that each treatment induced metabolic reprogramming. 
Metabolic reprogramming was depicted via NMR and GC-MS (Section 4.2.1 and 4.2.2, 
respectively) differential metabolic profiles. The differential metabolic profiles were 
explained by PCA/OPLS-DA models. Metabolic pathways associated with metabolic 




















Macrophages play a pivotal role in many biological processes including metabolic regulation, 
maintenance of tissue homeostasis and most importantly, in the immune response. These 
phagocytic cells are normally the primary regulators in the immune response during 
infections, including various bacterial infections (De Sousa et al., 2019). For in vitro studies on 
human macrophages, U937 monocytes-derived macrophages are a good model as they 
resemble the human macrophages in morphology, function, and metabolism (Mendoza-
Coronel and Mastanon-Arreola, 2016). As described in Chapter 2, the aim of the present study 
was to evaluate the effects of 1,25(OH)2D3 on the metabolome of U937 macrophage 
stimulated with Pam3CSK4. Experimentally, this metabolic profiling was carried out by 
applying a multi-platform approach that included NMR and GC-MS-based untargeted 
analyses (Chapter 3). This allowed a wide coverage of the intracellular metabolome.  
As presented in Chapter 4, applying various statistical analyses and modelling to mine the 
generated spectral data (from both NMR and GC-MS platforms) allowed the extraction of 
information that indicated a significant difference in the metabolome of the compared 
experimental groups (Figure 4.6A, 4.6C and 4.6E). From the variable selection (Figure 4.6B, 
4.6D and 4.6F), the identified discriminating metabolites (explaining group separation) were 
mapped onto metabolic pathways in an integrative manner, inferring thus significant 
pathways related to treatment effects. The results (Chapter 4) showed that treatment-related 
reprogramming of (macrophage) cellular metabolism spanned several amino acid pathways 
including galactose metabolism, arginine biosynthesis, glutathione metabolism, valine, 
leucine and isoleucine synthesis. This chapter interprets and discusses the obtained results 
(Chapter 4), in reference to the current literature, formulating and drawing relevant 
knowledge and conclusions regarding the metabolic effect of 1,25(OH)2D3 on U937 
macrophage stimulated with Pam3CSK4. The chapter is subdivided into three main sections: 
The results of U937 differentiation are discussed in Section 5.1, and the profiling of the U937 
macrophage cellular metabolome is discussed in Sections 5.2–5.3.  
 
5.1. U937 monocytes to macrophage differentiation  
As described in Chapter 3, the study was designed to firstly differentiate the U937 monocytes 
to macrophages. The latter mimics the in vivo immune cells responsible for the containment 
of M.tb during infection, providing a good (in vitro) model to study metabolomic 
reprogramming related to cellular immune responses to infection and/or other treatments, 
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such as 1,25(OH)2D3 in this case. Monocytes-derived macrophages can proliferate in culture 
and develop specialised functions. Furthermore, responses such as the inhibition of M.tb 
growth by macrophages in vivo can be observed in U937 macrophages in vitro (Daigneault et 
al., 2010).  
PMA is known as an effective inducer of macrophages from monocytes through mechanisms 
that include the activation of protein kinase C (PKC) (Song et al., 2015). In this study, the 
observed morphological changes in PMA-treated U937 cells (Figure 4.1B) evidently suggest 
that PMA successfully differentiated the U937 monocytes to macrophages. From our 
observations, PMA-treated cells were elongated, irregular in shape with rough edges and 
protrusions, which is a typical morphology of macrophages (Marcuello et al., 2018; 
McWhortera et al., 2013; Zamani et al., 2013). The morphology of macrophages correlates 
with their functions including proliferation, apoptosis, nuclear organisation and their 
phagocytic role in immunity (Rosales and Uribe-Querol, 2017; Versaevel et al., 2012).  
Macrophage elongation results from the uniaxial stretch of the cell (Pugin et al., 1998) 
whereas the cyclic biaxial stretch triggers an increase in the spread cell area (Matheson et al., 
2006). Both cell elongation and increase in spread cell area were observed in PMA-treated 
cells (Figure 4.1B). Functionally, the significance of such morphology is to form a link/bridge 
between the bacterial surface and the receptor of the macrophage that recognises the 
pathogen. Once the link has been established, the macrophage protrusions form a 
surrounding structure around the bacterial antigen. Subsequently, the antigen is absorbed 
into a phagosome created by the macrophage (Hirayama et al., 2018; Ueno and Wilson, 
2012).  
As presented in the results chapter (Section 4.1.1.), to complement morphological 
assessments (under a microscope), the differentiation of monocyte to macrophage was 
further confirmed by measuring CD14 count in both PMA supplemented cells and untreated 
cells using flow cytometry. The CD14 markers were measured as they are the main 
differentiation surface markers of myeloid lineage cells (Zamani et al., 2013). CD14 genes are 
among the macrophage-specific genes. During monocytes/macrophage differentiation, CD14 
proteins are abundantly expressed by macrophages (Contreras et al., 2015; Lehtonen et al., 
2007). The results (Chapter 4, Figure 4.3) showed that the expression of CD14 was higher in 
PMA-stimulated cells than in the U937 monocytes cultured in the absence of PMA. These 
findings are similar to those of Zhang et al. (2014), who differentiated THP-1 monocytes to 
macrophages using PMA, and found a significant increase in the expression of CD14 following 
cell treatment with PMA. Thus, an increase in CD14 expression is associated with the 
differentiation of monocytes to macrophages. Macrophages abundantly express CD14 as to 
detect pathogens during infection. Macrophages sense bacterial lipopolysaccharides through 
TLR2 and TLR4 to initiate phagocytosis (Anas et al., 2010). Both microscopic analyses and flow 
cytometry CD14 count measurements provided sufficient evidence to confidently confirm 
that PMA effectively differentiated U937 monocytes to macrophages.                                         
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To evaluate the effects of 1,25(OH)2D3 on the metabolome of U937 macrophage stimulated 
with Pam3CSK4, the multi-platform metabolomic analyses of U937 macrophages treated with 
Pam3CSK4, 1,25(OH)2D3, and a combination of Pam3CSK4 and 1,25(OH)2D3 was performed. 
These analyses showed differential changes in various metabolic pathways between the 
treatment conditions. The changes include an increase or decrease in levels of metabolites in 
pathways such as galactose metabolism, arginine biosynthesis, glutathione metabolism, 
valine, leucine and isoleucine biosynthesis as well as aminoacyl-tRNA biosynthesis. 
Biologically, these pathways are involved in different cellular functions and activities such as 
energy metabolism, regulation of redox reaction and protein synthesis. Thus, the following 
sections discuss these metabolic results in relation to biological functions: Section 5.2 looks 
at the regulation of energy metabolism and Section 5.3 discusses the reprogramming of 
metabolic pathways associated with amino acids.  
 
5.2. Regulation of energy metabolism  
The change in galactose metabolism observed in our study is associated with the metabolic 
reprogramming of energy metabolism. In our study, galactose metabolism was identified as 
the energy metabolism pathway reprogrammed in Pam3CSK4 stimulated cells, and in cells co-
treated with Pam3CSK4 and 1,25(OH)2D3 (Chapter 4, Table 4.1 and Figure 4.7). Galactose 
metabolism is associated with glycolysis and the Warburg effect, as discussed below. In 
mycobacterial infection, the reprogramming of the energy metabolism by the host 
determines survival, the virulence and persistence of M.tb in the host. The host usually utilises 
additional or alternative energy sources to improve energy production for the control of M.tb 
(Cumming et al., 2018; Shi et al., 2005). 
 
5.2.1. Galactose metabolism – “The Warburg effect” 
The presence of galactose during mycobacterial infection has been extensively described 
(Gough, 1932; Haworth et al., 1948). Galactose is a naturally occurring monosaccharide sugar 
with a similar chemical formula as glucose. Galactose only differs from glucose in the 
positioning of the carbon 4 (C4) hydroxyl (OH) group. The C4 OH positioning introduces some 
chemical and biochemical differences between galactose and glucose (Blackstock et al., 
1989). In a mammalian biological system, galactose serves as a source of energy and a 
substrate for the biosynthesis of several macromolecules (Liu et al., 2000). Galactose can be 
metabolised to glucose-6-phosphate (G6P) which can enter the glycolysis pathway. The 
conversation of galactose to G6P occurs via the Leloir pathway which was first described by 
Leloir in 1951. In the first step of the Leloir pathway, galactose is phosphorylated into 
galactose-1-phosphate (Gal1P) by galactokinase. Following that, Gal1P uridyltransferase 
catalyses the conversion of UDP-glucose and Gal1P to glucose-1-phosphate (G1P) and UDP-
galactose. The resulting G1P is converted to G6P by phosphoglucomutase. 
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Phosphoglucomutase catalyses the transfer of the phosphate group from C1 to C4 of glucose. 
G6P serves as a substrate for glycolysis. Cells, however, efficiently take up more glucose than 
galactose. Furthermore, galactose prevents the net production of ATP via glycolysis (Garedew 
et al., 2010). Hence, glucose-dependent energy production is preferred over the galactose-
dependent pathway. 
 
The UDP-galactose formed in the Leloir pathway can be converted to UDP-glucose by UDP-
galactose 4-epimerase. UDP-glucose plays a functional role in the synthesis of 
glycoconjugates via glycosylation reactions (Guo and Ye, 2010; Moradi et al., 2016). 
Glycosylation is an essential process for secondary protein processing and determines protein 
functioning (Arey, 2012). In our study, there was no significant difference in the relative 
concentration of galactose in cells treated with Pam3CSK4 only, 1,25(OH)2D3 only or co-treated 
with Pam3CSK4 and 1,25(OH)2D3. The relative concentration of galactose, however, decreased 
as the incubation period was increased from 12 hrs to 24 hrs. A gradual decrease in the 
relative concentration of galactose was also observed in the 16 and 24 hrs treatment 
conditions (Chapter 4, Table 4.1 and Figure 4.7). The gradual decline of galactose in the 16 
and 24 hrs treatment conditions suggest that galactose was metabolised over time. This 
gradual decrease is most likely associated with the up-regulation of glycolysis. The possibility 
of glycolysis up-regulation is supported by the findings obtained in Pam3CSK4 stimulated cells 
and in cells co-treated with Pam3CSK4 and 1,25(OH)2D3. Under these treatment conditions, a 
decrease in the relative concentration of glucose and an increase in the relative concentration 
of lactate was observed. These observations evidently suggest that glycolysis was up-
regulated. Our results correspond to those findings of Gleeson et al. (2016) and Shi et al. 
(2015), who also reported that glycolysis is up-regulated during M.tb infection in 
macrophages. This up-regulation has been linked with the containment of intracellular M.tb 
by the hosts’ immune response. This observation is similar to the Warburg effect in cancer 
cells.  
 
The Warburg effect is the metabolic phenomenon that is used to describe the up-regulation 
of glycolysis with the formation of lactate as the final product in cancer cells (Warburg, 1956). 
In recent years, the Warburg effect has been observed in non-cancerous cell types (Abdel-
Haleem et al., 2017). Our data further corresponds to the findings of Salamon et al. (2014), 
who reported that vitamin D enhanced the Warburg effect in M.tb infection. A shift in energy 
metabolism to glycolysis during M.tb infection is crucial for controlling the activity of M.tb as 
glycolysis promote inflammatory response against the bacteria through the generation of 




5.3. Reprogramming of metabolic pathways associated with amino acids  
The presence or absence of certain amino acids produced by the host during the 
mycobacterial infection can determine the inhibition, growth/survival and virulence of the 
mycobacterium in the host (Burke et al., 2018; Gouzy et al., 2014; Lyon et al., 1970). Amino 
acids detected in our study play an important role in the regulation of oxidation-reduction 
(redox) reaction, regulation of energy metabolism, synthesis of antimycobacterial 
compounds, nucleic acids synthesis and protein synthesis, including structure folding and 
function (Garrett et al., 2018; Kocic et al., 2012; Morris et al., 2017). Taken together, these 
amino acids shape the host’s immune response against mycobacterial infection.   
 
5.3.1. Arginine biosynthesis down-regulation by 1,25(OH)2D3 in Pam3CSK4 stimulated 
U937 macrophages 
The role of arginine in mycobacterial infection has been sufficiently investigated (Peteroy-
Kelly et al., 2003). Previous studies have shown that metabolic reprogramming during 
infection is associated with the changes in the metabolism of arginine (Luiking et al., 2003). 
Arginine is a semi-essential amino acid synthesised mainly from glutamate (Mizrahi and 
Warner, 2018). L-arginine serves as a precursor for the synthesis of reactive nitrogen species 
(RNS), polyamines, creatine, ornithine and urea cycle (Morris et al., 2017).  
Although in the current study arginine was not detected in all treatment conditions, 
significant changes in the concentration of metabolites associated with arginine 
biosynthesis—glutamate, ornithine and proline—were detected. A relatively high 
concentration of glutamate was observed in cells co-treated with Pam3CSK4 and 1,25(OH)2D3 
as compared to the untreated cells. A decrease in the relative concentration of glutamate was 
observed in cells treated with 1,25(OH)2D3 only. These changes were not observed in U937 
macrophages treated with Pam3CSK4 only. An increase in glutamate concentrations in cells 
co-treated with Pam3CSK4 and 1,25(OH)2D3 suggest that this treatment condition 
downregulates arginine biosynthesis—the conversion of glutamate to arginine. This could 
explain the relatively high concentration of glutamate observed in Pam3CSK4 and 1,25(OH)2D3 
co-treated U937 macrophages (Chapter 4, Table 4.1 and Figure 4.7A). The down-regulation 
of the arginine biosynthesis could be one of the metabolic effects of 1,25(OH)2D3 in Pam3CSK4 
treated U937 macrophages. 1,25(OH)2D3 probably initiates this arginine biosynthesis down-
regulation as the immune response against Pam3CSK4 action. In M.tb infection, arginine is 
used as a source of both carbon and nitrogen (Gupta et al., 2018; Hampel et al., 2015). 
Arginine starvation leads to the death of M.tb infected cells and ultimately, the killing of M.tb 
(Mizrahi and Warner, 2018; Tiwari et al., 2018). Our suggestion of arginine biosynthesis down-
regulation by 1,25(OH)2D3 in Pam3CSK4 treated U937 macrophages, however, contradicts the 
findings of Andrukhova et al. (2014), who reported that 1,25(OH)2D3 increases the availability 
of arginine, which subsequently leads to an increase in the synthesis of arginine-derived nitric 
oxide (NO). Furthermore, Rockett et al. (1998) reported that 1,25(OH)2D3 induces the 
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expression of the nitric oxide synthase 2 (NOS2) gene in M.tb infected human HL-60 
macrophage-like cell line. NOS2 encodes for NO synthase, an enzyme that catalyses the 
conversion of arginine to NO. NO has an antimycobacterial activity (Jamaati et al., 2017). We 
propose that the down-regulation of arginine biosynthesis seen in U937 macrophages co-
treated with Pam3CSK4 and 1,25(OH)2D3 could be the biochemical mechanism induced by 
1,25(OH)2D3 in U937 macrophages to inhibit NO synthesis. This suggests that 1,25(OH)2D3 
induces U937 macrophages to inhibit the mycobacterial-like effect of Pam3CSK4 through 
arginine starvation other than the use of NO. Although RNS such as NO has antimicrobial 
properties, overproduction of NO can cause mitochondrial dysfunction, DNA damage, 
changes in structure and function of protein mediators, as well as cell injury and cell death 
(Abdelmegeed et al., 2014; Groves et al., 1995; Song et al., 2014). Hence, NO downregulation 
is crucial in protecting the cells from these NO side effects. Hence, we propose arginine 
starvation rather than NO production by 1,25(OH)2D3 as the immune response against 
Pam3CSK4 stimulation. 
In addition to these observations, a relatively low concentration of ornithine was observed in 
cells co-treated with Pam3CSK4 and 1,25(OH)2D3. No significant changes in ornithine relative 
concentration were observed in the other treatments. Ornithine is a non-proteinogenic amino 
acid synthesised from the reaction of arginine with water, catalysed by arginase (Dimski, 
1994). Our observation further supports the notion that arginine biosynthesis was down-
regulated in Pam3CSK4 and 1,25(OH)2D3 co-treated cells. Arginine is a precursor of ornithine, 
and therefore, decreases in the synthesis of arginine will result in a decrease in ornithine 
synthesis. It has been shown that in M.tb infection, arginine is converted into ornithine, 
resulting in an increase in this metabolite (Hampel et al., 2015). Low concentration of arginine 
inhibits this reaction. A similar phenomenon was observed in our study, which further shows 
that arginine synthesis was inhibited by 1,25(OH)2D3 in Pam3CSK4 treated cells. In addition to 
arginine biosynthesis down-regulation, a relative decrease in ornithine could have been 
enhanced by ornithine decarboxylase. 1,25(OH)2D3 increases the activity of ornithine 
decarboxylase, an enzyme that catalyses the decarboxylation of ornithine. The increased 
activity of ornithine decarboxylase leads to a low concentration of ornithine (Sömjen et al., 
1983). Further enzyme-based investigations are needed to confirm this speculation.   
Taken together, the observed relative decrease in the concentration of arginine and ornithine 
suggest that 1,25(OH)2D3 decreases arginine biosynthesis in Pam3CSK4 treated U937 
macrophages. The decrease in arginine biosynthesis could be the metabolic mechanism 
induced by 1,25(OH)2D3 to activate the U937 macrophages immune response against 
Pam3CSK4 stimulation. Down-regulation of arginine biosynthesis is of importance in 
controlling the mycobacterial-like effect of Pam3CSK4. This speculation is based on the 
findings of Tiwari et al. (2018), who reported that arginine deprivation leads to M.tb killing 
through ROS accumulation, DNA damage, and rapid sterilisation of M.tb. Arginine is a crucial 
source of both carbon and nitrogen needed for M.tb survival (Hampel et al., 2015).  
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5.3.2. Glutathione metabolism down-regulation in U937 macrophages co-treated 
with Pam3CSK4 and 1,25(OH)2D3  
 
Changes in the cellular glutathione (GSH) concentration in the presence of mycobacteria have 
been previously investigated (Dayaram et al., 2006; Guerra et al., 2011). GSH is an essential 
tripeptide antioxidant synthesised from glutamate, cysteine and glycine in two sequential 
ATP-dependent steps (Lu, 2009). The first step is the synthesis of γ-glutamylcysteine from 
glutamate and cysteine in a reaction catalysed by glutamate-cysteine ligase (GCL). The second 
step is the addition of glycine to γ-glutamylcysteine to form GSH in a reaction catalyzed by 
GSH synthetase (Mari et al., 2010). GSH maintains the cellular redox state through the active 
thiol group present in the cysteine residue of GSH. The thiol group of cysteine regulates the 
redox state by directly detoxifying ROS and RNS (Cooper et al., 2011). A decrease in 
intracellular GSH leads to an increase in ROS, which ultimately leads to oxidative stress (OS). 
The latter is a process by which cells and tissues produce excessive ROS compared to 
antioxidants. The imbalance between ROS and antioxidants can lead to chronic inflammation 
(Hussain et al., 2016). OS is a common phenomenon in mycobacterial infections such as TB. 
In active TB, OS is induced to counteract the disease and kill M.tb (Goyal et al., 2017; Shastri 
et al., 2018).  
Previous studies have shown that GSH can protect the host against microbial infection by 
activating T lymphocytes and natural killer cells (Guerra et al., 2011; Guerra et al., 2012). 
Additionally, GSH reacts with NO to form S-nitrosoglutathione (GSNO). The latter increases 
the activity of NO in inhibiting microbial growth. NO from the GSNO complex is released at 
the site of infection to induce microbial death (Venketaraman et al., 2003). In cases where 
GSH levels are decreased, an increase in OS is usually observed (Mohod et al., 2008). For 
instance, patients with active TB have decreased levels of GSH during the initial stages of 
infection (Venketaraman et al., 2008). Decreased levels of GSH lead to OS, which contributes 
towards the control of M.tb infection (Wu et al., 2018). In the present study, decreased GSH 
was detected in U937 macrophages treated with a combination of Pam3CSK4 and 1,25(OH)2D3 
in the 12 hrs treatment. GSH was not detected in the 16 and 12 hrs treatment conditions. In 
U937 macrophages treated with a combination of Pam3CSK4 and 1,25(OH)2D3 in the 12 hrs 
treatment, GSH concentration was relatively low. These findings suggest that Pam3CSK4 and 
1,25(OH)2D3 co-treatment down-regulates glutathione synthesis. A decrease in GSH would 
favour U937 macrophages oxidative response to the mycobacterial-like effect of Pam3CSK4. 
The effect of supplementary 1,25(OH)2D3 on GSH metabolism in mycobacterial infection is still 
enigmatic and remains to be investigated. To our knowledge, this is the first study to show 
the relationship between mycobacterial infection, supplementary 1,25(OH)2D3 and GSH 
metabolism in macrophages using metabolomics. A recent study by Vrieling et al. (2020) only 
investigated the relationship between mycobacterial infection and GSH metabolism. In their 
study, Vrieling et al. (2020) reported an increase in GSH concentration following M.tb 
infection. In our study, however, we observed a decrease in GSH when Pam3CSK4 treated 
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U937 macrophages are supplemented with 1,25(OH)2D3. This observation suggests that 
1,25(OH)2D3 down-regulates GSH synthesis in Pam3CSK4 treated U937 macrophages. This 
could be the immune response mechanism to induce OS for the inhibition of Pam3CSK4 
mycobacterial-like activity. Our observation of the decrease in GSH in the presence of 
1,25(OH)2D3 contradicts the findings of Jain and Micinski (2013). These authors reported that 
1,25(OH)2D3 up-regulates GSH synthesis by up-regulating glutamate-cysteine ligase (GCL) in 
U937 monocytes. The differences observed in our study and that of Jain and Micinski (2013) 
suggest that the metabolic effect of 1,25(OH)2D3 on GSH metabolism differs between 
monocytes and macrophages. Further studies should be done to confirm the absence of 
increased GSH concentrations using standard biochemical assays. 
Subsequently, glycine and glutamate (GSH precursors) were also observed in our study. 
Glycine and glutamate are nonessential amino acids that are key excitatory neurotransmitters 
involved in metabolic, bioenergetic, biosynthetic and oncogenic signalling pathways (Alves et 
al., 2019; Willard and Koochekpour, 2013). Mycobacteria utilise these metabolites as a 
nitrogen source needed for mycobacterial growth and replication (Cowley et al., 2004; Lyon 
et al., 1970; Ratledge, 1976). In the current study, glutamate concentration was not 
significantly affected in Pam3CSK4 stimulated macrophages, however, the concentration of 
glutamate was relatively increased in cells co-treated with Pam3CSK4 and 1,25(OH)2D3. This 
observation suggests that 1,25(OH)2D3 inhibits the consumption of glutamate in Pam3CSK4 
treated U937 macrophages, meaning that the use of glutamate in GSH synthesis was 
inhibited. Accordingly, the GSH concentration was relatively decreased in cells co-treated 
with Pam3CSK4 and 1,25(OH)2D3. These observations further show that Pam3CSK4 and 
1,25(OH)2D3 co-treatment down-regulated GSH synthesis. The increase of glutamate and the 
decrease in GSH levels observed in cells co-treated with Pam3CSK4 and 1,25(OH)2D3 could be 
the mechanism used by the cells relating to allow OS. In this instance, OS would be necessary 
to produce ROS, which would inhibit the mycobacterial-like activity of Pam3CSK4. Our 
suggestion agrees with the study by Kelly et al. (2015), who reported an increase in ROS 
production in Pam3CSK4 treated macrophages. Furthermore, Matta and Kumar (2016) also 
reported an increase in ROS in M.tb infected macrophages as as an immune response against 
this bacterium. ROS, such as hydrogen peroxide, diffuses through the cell membrane of the 
pathogen into the cytoplasm and damages the DNA, thus leading to the death of the pathogen 
(Slauch, 2011). 
In addition to glutamate, the concentration of glycine was relatively increased in all treatment 
conditions at 12 hrs. A gradual decrease in the relative concentration of glycine was also 
observed in the 16 and 24 hrs treatment conditions (Chapter 4, Table 4.1 and Figure 4.7). This 
gradual decrease could be associated with glycine degradation over time. The relative 
concentration of glycine was slightly higher in Pam3CSK4 treated U937 macrophages as 
compared to Pam3CSK4 and 1,25(OH)2D3 co-treated U937 macrophages over time. This 
suggests that 1,25(OH)2D3 induces glycine degradation in Pam3CSK4 treated U937 
macrophages. We propose that the relative low glycine concentration in U937 macrophages 
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is associated with biochemical processes such as energy metabolism and protein synthesis 
other than GSH synthesis. This suggestion is based on the evidence that GSH concentration 
was relatively low in U937 macrophages co-treated with Pam3CSK4 and 1,25(OH)2D3 (Chapter 
4, Table 4.1 and Figure 4.7A). Taken together, our findings suggest that one of the metabolic 
effects of 1,25(OH)2D3 in Pam3CSK4 treated U937 macrophages is the down-regulation of GSH 
synthesis. Hence, GSH was relatively decreased in U937 macrophages co-treated with 
Pam3CSK4 and 1,25(OH)2D3. GSH synthesis is probably inhibited by 1,25(OH)2D3 in order to 
allow the oxidative response against Pam3CSK4 in U937 macrophages.  
    
5.3.3. Reprogramming of valine, leucine and isoleucine biosynthesis in U937 
macrophages treated with Pam3CSK4 only and 1,25(OH)2D3 only  
The role of branched-chain amino acids (BCAAs)— valine, leucine and isoleucine—in microbial 
infection has been extensively described (Lobel et al., 2015; Kaiser and Heinrichsa, 2018; Kim 
et al., 2017). BCAAs are essential amino acids that consist of hydrophobic side chains. They 
are the main contributors to the hydrophobic side chains required for the structure and 
function of proteins (Shimomura and Harris, 2006). BCAA catabolism starts with the 
conversion of BCAAs in a transamination reaction catalysed by branched-chain 
aminotransferase (BCAT) into their respective α-keto acids (branched-chain keto acids; 
BCKAs). These include α-keto-β-methylvaleric acid, α-ketoisovaleric acid and α-ketoisocaproic 
acid. The second step is the oxidative decarboxylation of BCKAs by the branched-chain 
ketoacid dehydrogenase complex. This reaction yields isovaleryl-CoA, α-methylbutyryl-CoA 
and isobutyryl-CoA. These are precursors of acetoacetate, acetyl-CoA and succinyl-CoA 
(Burrage et al., 2014). Acetoacetate, acetyl-CoA and succinyl-CoA are utilised in energy 
metabolism (TCA cycle) and for biosynthetic purposes (e.g. lipid biosynthesis) (Wanders et al., 
2012). BCAAs are essential in protein synthesis, energy metabolism and the immune response 
(Holeček, 2018; Nie et al., 2018; Platell et al., 2000). 
Valine and leucine were detected in the current study. Stimulation of U937 macrophages with 
only Pam3CSK4 induced a relative increase in the concentration of valine in the 12 and 24 hrs 
treatment conditions (Chapter 4, Table 4.1 and Figure 4.7A). These changes were, however, 
not detected in the 16 hrs treatment conditions. The relative increase in valine concentration 
in Pam3CSK4 is most likely associated with an up-regulation of BCAA (particularly valine) 
biosynthesis. The biosynthesis of BCAAs by the U937 macrophages probably support the 
activity of Pam3CSK4. Our suggestion is supported by the study of Awasthy et al. (2009) who 
reported that BCAAs biosynthesis is crucial for intracellular survival of M.tb. BCAAs 
(particularly valine) is used as a nitrogen donor by intracellular M.tb in macrophages (Borah 
et al., 2019). 
In cells treated with 1,25(OH)2D3 only (24 hrs treatment), a relatively low concentration of 
leucine was observed (Chapter 4, Table 4.1 and Figure 4.7C). Leucine was, however, not 
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detected in the 12 and 16 hrs treatment conditions. A decrease in leucine in cells treated with 
1,25(OH)2D3 only in 24 hrs treatment suggests that 1,25(OH)2D3 supplementation to U937 
macrophages downregulates BCAA biosynthesis. We, therefore, propose that a decrease of 
leucine could be the results of BCAA oxidation (particularly leucine) by the U937 macrophages 
supplemented with 1,25(OH)2D3. The relationship between 1,25(OH)2D3 and BCAA 
biosynthesis in macrophages is yet to be investigated in the literature. Previous studies, 
however, have reported that immune cells including macrophages, oxidise BCAAs to produce 
precursors for energy metabolism and the synthesis of new immune cells (Calder, 2006; 
Negro et al., 2008; Platell et al., 2000; Zhang et al., 2017). The metabolic profiling of U937 
macrophages co-treated with Pam3CSK4 and 1,25(OH)2D3 did not show any changes in BCAAs 
(Chapter 4, Table 4.1 and Figure 4.7). The metabolic effect of 1,25(OH)2D3 on BCAA synthesis 
in Pam3CSK4 treated cells remains unclear. Further investigations are needed to elucidate the 
effect of 1,25(OH)2D3 on BCAA biosynthesis in Pam3CSK4 stimulated cells. 
 
5.3.4. Easing of Pam3CSK4 effects by aminoacyl-tRNA biosynthesis reprogramming 
Aminoacyl-tRNA or transfer RNA (tRNA) biosynthesis is another pathway altered in M.tb 
infection. This pathway is concerned with the attachment of amino acids to relevant tRNA in 
the process catalysed by a multi-enzyme aminoacyl-tRNA synthetase. This process is a 
requirement for protein synthesis (Gadakh and Van Aerschot, 2012; Yanagisawa et al., 2010). 
Inhibiting aminoacyl-tRNA synthetase prevents the synthesis of proteins required by the 
pathogen for growth and virulence (Van de Vijver et al., 2009). Our detection of significant 
alterations in the aminoacyl-tRNA biosynthesis pathway could be due to an immune response 
mechanism following U937 macrophages stimulation with Pam3CSK4. Supplementing the cells 
with 1,25(OH)2D3 most likely counteracts the activity of Pam3CSK4 by targeting aminoacyl-
tRNA synthetases. Aminoacyl-tRNA synthetases are validated targets for many therapeutic 
strategies against infectious diseases. Most therapeutics control infections by inhibiting the 
messenger RNA (mRNA) translation machinery (Dewan et al., 2014). Previous studies have 
shown that anti-TB compounds can inhibit M.tb by targeting specific M.tb aminoacyl-tRNA 
synthetases (Hu et al., 2013; Kovalenko et al., 2019; Soto et al., 2018; Zhu et al., 2015). 
Unfortunately, it cannot be determined from the results generated in our study whether 
aminoacyl-tRNA biosynthesis was down- or up-regulated in each treatment condition. This is 
due to the fact that aminoacyl-tRNA biosynthesis involves all the standard amino acids. In this 
instance, one cannot pinpoint a specific amino acid that is responsible for the changes 
observed. Nonetheless, the results show that aminoacyl-tRNA biosynthesis was significantly 
altered in Pam3CSK4 treated cells supplemented with or without 1,25(OH)2D3. The exact 
metabolic effects of 1,25(OH)2D3 on aminoacyl-tRNA biosynthesis in Pam3CSK4 treated U937 
macrophages remain unclear in the present study. Little is known about the effect of 
1,25(OH)2D3 on aminoacyl-tRNA biosynthesis in literature. Future studies using enzyme assays 
are needed to measure the activity of specific aminoacyl-tRNA synthetases involved in protein 
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synthesis in U937 macrophages treated with Pam3CSK4, 1,25(OH)2D3 and a combination of 
Pam3CSK4 and 1,25(OH)2D3. This will help to determine the regulation of aminoacyl-tRNA 

























CONCLUSION AND FUTURE PERSPECTIVES 
 
1H NMR spectroscopy and GCxGC-TOFMS based metabolomics successfully detected and 
identified metabolites discriminating metabolic profiles of U937 macrophages treated with 
Pam3CSK4, 1,25(OH)2D3 and a combination of Pam3CSK4 and 1,25(OH)2D3. Discriminatory 
metabolites that distinguish the study groups have been linked to energy metabolism 
(galactose metabolism, glycolysis—the Warburg effect), regulation of redox reaction (arginine 
biosynthesis and glutathione metabolism), amino acid and protein synthesis (aminoacyl-tRNA 
biosynthesis). Together, these metabolic pathways have also been implicated in the immune 
responses during mycobacterial infection.  
 
Novel aspect  
Previous metabolomics-based mycobacterial studies focused solely on evaluating the 
metabolic changes induced by mycobacterial infection from biological sample matrices such 
as serum, plasma, lung tissue and spleen tissue. In addition, a limited number of studies have 
investigated the metabolic effects of 1,25(OH)2D3 in the presence of mycobacterial infection. 
The aim of the present study was to evaluate the metabolic effects of supplementary 
1,25(OH)2D3 in mycobacterial stimulated macrophages using 1H NMR spectroscopy and 
GCxGC-TOFMS metabolomics. Although this is an in vitro study, the metabolic changes in 
mycobacterial stimulated cells co-treated with Pam3CSK4 and 1,25(OH)2D3 have been 
identified. The generated data revealed that supplementary 1,25(OH)2D3 induces metabolic 
reprogramming in mycobacteria stimulated cells. The results suggest that 1,25(OH)2D3 
promotes the elimination of bacterial infection by the macrophages and is therefore 
beneficial in the immune response against mycobacterial infection. To further substantiate 
our findings, additional confirmatory investigations using actual M.tb are needed. Such 
studies may contribute to the understanding of whether or not 1,25(OH)2D3 is significantly 
beneficial in eliminating M.tb infection.     
 
Revisiting hypothesis 
It was hypothesized that: Metabolomics can detect the metabolic changes induced by 
Pam3CSK4 stimulation of macrophages supplemented with or without 1,25(OH)2D3.  
The results (Chapter 4, Section 4.2 and appendix data) showed differences in the metabolic 
profiles of U937 macrophages stimulated with Pam3CSK4 and supplemented with or without 
1,25(OH)2D3. Based on these findings, the proposed hypothesis was accepted.  
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The null hypothesis was therefore rejected as it states that: Metabolomics cannot detect the 
metabolic changes induced by Pam3CSK4 stimulation of macrophages supplemented with or 
without 1,25(OH)2D3. 
Limitations of the study 
• The present study used in vitro models (U937 macrophages and Pam3CSK4) due to the 
limitation in specialised equipment and M.tb infected serum samples. The in vitro models 
do not give the exact metabolic events that occur in vivo during M.tb. Thus, the 
physiological relevance of the in vitro models differs from that of the in vivo systems. 
Nonetheless, the present study gives the possible metabolic events that occur in M.tb 
infection with or without 1,25(OH)2D3. 
 
• The study only focused on the intracellular metabolome. The results obtained do not 
account for the extracellular metabolome. Hence, the obtained results do not give the 
complete picture of all the metabolic events associated with each treatment condition. 
Nevertheless, the metabolites detected in this study allowed us to speculate on the 
possible metabolic events occurring under each treatment condition. 
 
 
Future perspectives  
• Quantitative analysis of metabolites implicated in U937 macrophages treated with 
Pam3CSK4, supplemented with 1,25(OH)2D3 and co-treated with Pam3CSK4 and 
1,25(OH)2D3. Quantitative analysis will provide the actual concentration of each 
significantly altered metabolite in the study groups. This information will help understand 
the extent to which 1,25(OH)2D3 effects a specific metabolites in U937 macrophages 
stimulated with or without Pam3CSK4. Such knowledge can be used to further confirm 
whether 1,25(OH)2D3 is significant in eliminating the mycobacterial infection. 
 
• Future studies will also require the use of additional analytical techniques such as LC-MS 
to detect as many metabolites as possible. The use of LC-MS will allow the detection of 
thermally unstable, involatile and ionic compounds that could not be detected using NMR 
and GCxGC-TOFMS. This additional analytical technique will expand the number of 
metabolites detected and possibly the number of metabolic pathways reprogrammed in 
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The data presented in this chapter contains additional and complementary data that was not 
included in the main text. Raw data and any additional data which are not included in this 
chapter are available upon request from the Department of Biochemistry, University of 
Johannesburg.  
 
1. Overlaid spectra 1H NMR spectroscopy spectrum of metabolic profiling of U937 
macrophages treated with Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 
1,25(OH)2D3 as well as control cells(untreated) – 16-hrs treatment.  
 
Figure A1: Overlaid 1H NMR spectra acquired using a 500 MHz Bruker NMR spectrometer (16 h 
treatment). The spectra represent the metabolic profiling of (A) control cells (untreated), (B) 
Pam3CSK4 stimulated cells, (C) 1,25(OH)2D3 treated cells and (D) Pam3CSK4/1,25(OH)2D3 
supplemented cells incubated for 16 hrs. The labelled peaks are potential signatory metabolites 
identified from the Human Metabolome Database (HMDB) (http://www.hmdb.ca/) and relevant 
published literature (Govindaraju et al., 2000; Mickiewicz et al., 2014; Subramani et al., 2016). All 
spectra were referenced to TSP at δ 0.0 ppm and α-glucose at δ 5.53 ppm. 1,25(OH)2D3: 1,25-




2. Overlaid spectra 1H NMR spectroscopy spectrum of metabolic profiling of U937 
macrophages treated with Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 
1,25(OH)2D3 as well as control cells(untreated) – 24-hrs treatment. 
 
Figure A2: Overlaid 1H NMR spectra acquired using a 500 MHz Bruker NMR spectrometer (24 hrs 
treatment). The spectra represent the metabolic profiling of (A) control cells (untreated), (B) 
Pam3CSK4 stimulated cells, (C) 1,25(OH)2D3 treated cells and (D) Pam3CSK4/1,25(OH)2D3 
supplemented cells incubated for 24 hrs. Potential signatory metabolites differentiating the study 
groups are shown as labelled peaks. These were identified from the Human Metabolome Database 
(HMDB) (http://www.hmdb.ca/) and relevant published literature (Govindaraju et al., 2000; 
Mickiewicz et al., 2014; Subramani et al., 2016). All spectra were referenced to TSP at δ 0.0 ppm and 




3. Metabolic profiling of U937 treated with Pam3CSK4, 1,25(OH)2D3 and 
Pam3CSK4/1,25(OH)2D3 –PCA modelling (16-hrs treatment). 
 
 
Figure A3: PCA modelling. (A) PCA scores scatter plot of control cells, Pam (Pam3CSK4), VitD 
(1.25(OH)2D3), and Pam3CSK4/Vit D (Pam3CSK4/1.25(OH)2D3) treated cells. The between-groups 
variation is explained by the y-axis and the within-group variation is explained by the x-axis (R2= 0. 
997, Q2= 0. 95, components = 14). No strong outliers were detected using Hotelling's T2 test at a 95% 
confidence level. (B) DModX shows two moderate outliers with DModX values greater than critical 
value, DCrit(0.05) (red dotted line). These outliers had no variable(s) with critical deviation from the 









4. Metabolic profiling of U937 treated with Pam3CSK4, 1,25(OH)2D3 and 
Pam3CSK4/1,25(OH)2D3 – PCA modelling (24-hrs treatment).  
 
 
Figure A4: PCA modelling. (A) PCA scores scatter plot of Pam (Pam3CSK4), VitD (1.25(OH)2D3), and 
Pam3CSK4/Vit D (Pam3CSK4/1.25(OH)2D3) treated cells as well as the control cells. No strong outliers 
were detected according to Hotelling's T2 test at a 95% confidence level. Moderate outliers were 
detected using DModX (B). These are observations with DModX values greater than critical value, 
DCrit(0.05) (red dotted line). (R2= 0.972, Q2= 0.863, components =7). Moderate outliers had no 










5. Metabolic profiling of U937 treated with Pam3CSK4, 1,25(OH)2D3 and 
Pam3CSK4/1,25(OH)2D3 – OPLS-DA modelling (16-hrs treatment). 
 
Figure A5: OPLS-DA modelling and variable selection. (A) An OPLS-DA scores scatter plot separating 
the control cells vs. Pam3CSK4 (Components: 1+8+0, R2X= 0.995, R2Y= 0.999, Q2= 0.99, CV-ANOVA p-
value = 9.31628 × 10-6). The model displays the separation of the two classes in horizontal (t1) 
direction; and within-class variability is expressed in the vertical (to[1]) direction. (B) the loading S-
plot displays discriminant variables – the variables that are situated in the extreme end of the S-plot 
are statistically relevant and represent prime candidates as discriminating variables. (C) An OPLS-DA 
scores scatter plot and (D) the loading S-plot of the control cells vs. 1,25(OH)2D3. A clear separation 
can be seen between the two classes (Components: 1+8+0, R2X = 0.992, R2Y = 0.999, Q2 = 0.983, CV-
ANOVA p-value =5.90137 × 10-5). (E) An OPLS-DA scores scatter plot and (F) the loading S-plot of the 
control cells vs. Pam3CSK4/1,25(OH)2D3 (Components:1+3+0, R2X = 0.968, R2Y = 0.98, Q2 = 0.945, CV-
ANOVA p-value =1.64464).  
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6. Metabolic profiling of U937 treated with Pam3CSK4, 1,25(OH)2D3 and 
Pam3CSK4/1,25(OH)2D3 – OPLS-DA modelling (24-hrs treatment). 
 
Figure A6: OPLS-DA modelling and variable selection. (A) An OPLS-DA scores scatter plot separating 
the control cells vs. Pam3CSK4 (Components: 1+6+0, R2X= 0.994, R2Y= 0.999, Q2= 0.973, CV-ANOVA p-
value =0.00251). The model displays the separation of the two classes in horizontal (t1) direction; and 
within-class variability is expressed in the vertical (to[1]) direction. (B) the loading S-plot showing the 
discriminant variables.  Potential discriminating variables are situated in the extreme end of the S-
plot. (C) An OPLS-DA scores scatter plot and (D) the loading S-plot of the control cells vs. 1,25(OH)2D3. 
A clear separation can be seen between the two classes (Components: 1+8+0, R2X = 0.997, R2Y = 1, Q2 
= 0.99, CV-ANOVA p-value = 0.00196). (E) An OPLS-DA scores scatter plot and (F) the loading S-plot 
of the control cells vs. Pam3CSK4/1,25(OH)2D3 (Components: 1+6+0, R2X = 0.987, R2Y = 0.999, Q2 = 





7. Volcano plot showing significant, discriminatory metabolites between control cells vs. 
Pam3CSK4; and control cells vs. Pam3CSK4/1.25(OH)2D3 supplemented cells. The metabolic 
profiling was performed using GCxGC–TOFMS (12-hrs treatment). 
 
Figure A7: Volcano plot of significant metabolites. (A) Volcano plot of control cells vs. Pam3CSK4 
stimulated; and that of (B) control cells vs. Pam3CSK4/1.25(OH)2D3 supplemented cells. Significant 
discriminatory variables (metabolites) are located away from the origin (0) of the plot. They are 







8. PCA modelling of GCxGC-TOFMS based metabolic profiling of control cells vs. Pam3CSK4; 
and control cells vs. Pam3CSK4/1.25(OH)2D3 supplemented cells (12-hrs treatment). 
Figure A8: PCA modelling. PCA scores scatter plot of (A) control vs. Pam3CSK4 stimulated cells; and (B) 
control vs. Pam3CSK4/1.25(OH)2D3 supplemented cells. The within-group separation and between-
















9. PLS-DA modelling of control vs. Pam3CSK4 stimulated cells; and control cells vs.  
Pam3CSK4/1.25(OH)2D3 supplemented cells (12-hrs treatment). 
 
Figure A9: PLS-DA modelling. PLS-DA scores scatter plot separating (A) control vs. Pam3CSK4 
stimulated cells; and (B) control vs. Pam3CSK4/1,25(OH)2D3 supplemented cells. Component 1 shows 
















10. Selection of variables responsible for separation observed in PLS-DA score scatter plots 
generated from the GC-MS based metabolic profiling (12-hrs treatment).  
 
Figure A10: VIP scores. VIP scores showing potential signatory metabolites discriminating (A) control 
cells vs. Pam3CSK4 stimulated cells; and (B) control cells vs.  Pam3CSK4/1.25(OH)2D3 supplemented 
cells. Discriminatory metabolites have VIP > 1.  
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11. OPLS-DA modelling and variable selection of GC-MS based metabolic profiling (12-hrs 
treatment). 
 
Figure A11: OPLS-DA modelling and variable selection. OPLS-DA scores scatter plot separating (A) 
control cells vs. Pam3CSK4 stimulated cells (Permutation analysis: Q2 = -0.1, R2Y=0.918); and (B) 
control cells vs. Pam3CSK4/1,25(OH)2D3 supplemented cells (Permutation analysis: Q2 = -0.1, 
R2Y=0.918). Discriminatory features responsible for the separation observed in the OPLS-DA scores 
scatter plots are shown in the loadings S-plots (C) control cells vs. Pam3CSK4 stimulated cells and (D) 






12. Metabolic pathway analysis  
 
Table A1: Most significantly altered metabolic pathway in U937 macrophages treated with 
Pam3CSK4, 1,25(OH)2D3 and a combination of both Pam3CSK4 and 1,25(OH)2D3. 
Metabolic 
Pathway 
Total  Expected  Hits  Raw p-
value 








48 0.84 8 6.62 x 10-7 1.42 x 101 5.56 x 10-5  5.56 x 10-5 0.00 
Arginine 
biosynthesis 
14 0.24 4 6.51 x 10-5 9.64 5.40 x 10-3  1.89 x 10-3 0.18 
Galactose 
metabolism 




8 0.14 3 2.49 x 10-4 8.30  2.02 x 10-2 5.24 x 10-3 0.00 
Glutathione 
metabolism 
28 0.49 4 1.13 x 10-3 6.79  9.00 x 10-2 1.89 x 10-2 0.12 
 
 
 
